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Résumé 
Une large gamme d’événements cellulaires est régulée par la SUMOylation des 
protéines.  Cette modification post-traductionnelle est impliquée dans le cancer notamment 
dans la leucémie promyélocytaire aigue.  À ce jour, peu d’études à grande échelle ont porté 
sur l’identification des sites de modification.  Ce mémoire présente une approche 
protéomique quantitative unique qui combine une double purification par affinité au niveau 
des protéines cibles ainsi que des peptides modifiés. 
 
L’approche la plus répandue de purification des protéines SUMOylés implique 
l’utilisation d’une forme de SUMO modifié avec une étiquette (His6-SUMO). A ce jour, les  
approches permettant l’enrichissement au niveau peptidique nécessite une forme mutante 
de SUMO.  
 
Notre analyse consiste à premièrement enrichir en protéines SUMOylés dans les 
cellules humaines vierges ou sur exprimant His6-SUMO-1/3 en présence ou pas de trioxyde 
de diarsenic, un traitement de leucémie promyélocytaire aigue. Par la suite, les échantillons 
sont digérés et les peptides obtenus des protéines SUMOylés conservent un branchement 
caractéristique. Les peptides sont soit immunoprécipités avec un anticorps spécifique au 
branchement SUMO ou directement analysés par nano LC/LC-MS/MS par un spectromètre 
de masse LTQ-Orbitrap.  Une analyse manuelle des données révèle des fragments 
caractéristiques correspondant à la chaîne latérale de SUMO.  L’originalité de l’approche 
réside dans l’identification quantitative et sans ambigüité des sites de SUMOylation. Cette 
approche a permis l’identification de 17 et 3 sites de SUMO-3 et SUMO-1 respectivement 
dans les cellules HEK293. Finalement, la SUMOylation de PML est induite suite au 
traitement d’arsenic.  
 
Mots-clés : SUMOylation, spectrométrie de masse, purification par affinité, 
identification de sites de SUMOylation 
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Abstract 
A wide range of cellular events are regulated by protein SUMOylation. This 
posttranslational modification was involved in APL (acute promyelocytic leukemia). Only 
a few large scale studies in mammalian cells have focused on identifying the conjugation 
sites. This thesis presents a unique quantitative proteomics approach that combines double 
affinity purification at the protein and peptide level. 
 
A common approach to purification of SUMOylated proteins involves the use of a 
tagged SUMO (His6-SUMO). To date, the SUMO peptide isolation is addressed using an 
engineered SUMO.  
 
In presence or absence of arsenic trioxide, a treatment of APL, mock and His6-
SUMO1/3 expressing cells are lysed and the SUMOylated proteins are isolated under 
denaturing conditions. Subsequently, these samples are digested and the peptides bearing 
the modification site bear a specific SUMO stub. They are either immunoprecipitated with 
an anti SUMO stub antibody or directly analyzed by nano LC coupled to an LTQ-Orbitrap 
mass spectrometer. Manual analysis of the data reveals characteristic fragmentation 
corresponding to the side chain of SUMO. The originality of the approach lies in the 
quantitative and unambiguous identification of SUMOylation sites in vivo. This approach 
allowed the identification of 17 and 3 sites of SUMO-3 and SUMO-1, respectively, in 
HEK293 cells. Finally, PML was identified as the major SUMOylation target following 
arsenic treatment. 
 
Keywords: SUMOylation, mass spectrometry, affinity purification, identification of 
SUMOylation sites. 
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1.1 SUMOylation process in the cell 
 
Post-translational modifications (PTMs) represent universal and fundamental 
mechanisms by which protein function, activity, stability and localization can be 
regulated. These modifications extend significantly the diversity of the proteome. PTMs 
are divided into two groups: proteolytic cleavages and covalent modifications. There are 
over 150 different covalent modifications on a variety of amino acid side chains (Voet 
and Voet 1995), among these are small chemical group modifications such as 
acetylation, phosphorylation or larger macromolecules attachment such as ubiquitylation 
and SUMOylation, the latter being the primary focus of the present study.  
 
1.1.1 Discovery of SUMO 
 
In the 1970’s, the first protein acting as a ubiquitin-like (UBL) modifier was 
discovered : ubiquitin (Hochstrasser 2009). However, the first documented report of a 
related small ubiquitin modifier (SUMO) was only made  20 years later by Mhajan et al. 
for Ran GTPase 1 (RanGap1) covalently modified by SUMO-1 in mammals (Mahajan, 
Delphin et al. 1997). At the present day, at least nine UBLs are shown to covalently 
modify their targets, and it is suspected that additional UBLs are likely to be discovered 
in the future (Hochstrasser 2009). Regardless of their low sequence similarity to 
ubiquitin, all UBLs share a common 3D structure: the ubiquitin fold. For instance, 
although SUMO-1 and ubiquitin share only 18% sequence identity, SUMO has the 
characteristic ββαββαβ fold of the ubiquitin protein family (Bayer, Arndt et al. 1998) as 
observed in Figure 1.1. 
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Figure 1.1: Overlay SUMO-1 (black) and ubiquitin (red) (Bayer, Arndt et al. 1998) 
 
SUMO is expressed in all eukaryotic cells and in different cell types in multicellular 
organisms. Yeasts have a single isoform of SUMO, while in vertebrates, four paralogs of 
SUMO (SUMO1-4) are expressed (Saitoh and Hinchey 2000), and in plants eight 
versions of SUMO have been identified (Kurepa, Walker et al. 2003).  
 
In humans, SUMO-1 is the most studied paralog and hundreds of SUMO1-2-3 
conjugates have been identified. SUMO1 and SUMO2/3 share about 50% similarity, but 
SUMO-2 and SUMO-3 differ only by 4 residues. SUMO1 and SUMO2/3 seem to have 
different functions since they conjugate different substrates in vivo and have different 
responses to stress (Saitoh and Hinchey 2000). The role of SUMO-4 is still unknown, no 
conjugates have been detected in vivo and its in vivo maturation into a conjugation-
competent form still remains unclear (Bohren, Nadkarni et al. 2004). 
 
1.1.2 SUMO conjugation, processing and deconjugation 
 
UBLs not only share a common structure, but they use similar conjugation 
mechanisms requiring a multi-stage ATP-dependent enzymatic cascade (Hochstrasser 
2009). Specific and highly dynamic machinery is responsible for SUMO conjugation: 
the formation of an isopeptide bond between the C-terminal glycine of the mature 
SUMO and the amino ε group of the target’s specific lysine residue. The specificity of 
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the reversible SUMO conjugation is regulated by a specialized set of enzymes (Figure 
1.2). 
 
Figure 1.2: SUMO pathway: activation, conjugation and deconjugation adapted from 
(Petsko and Ringe 2004) 
 
 
1.1.2.1 SUMO conjugation 
 
The SUMO conjugation proceeds in three steps requiring a cascade of enzymes: E1, 
E2 and E3 which results in the formation of an isopeptide bond (Figure 1.3). 
 
First, the SUMO-Activating enzyme (E1), a dimer composed of Sae1 and Sae2 in 
mammals, forms a thioester bond with the carboxy group of the SUMO protein and the 
cys173 of Sae2 (Ulrich 2008). This step requires the hydrolysis of one ATP molecule. 
 
Then, SUMO is transferred to an E2 enzyme. Contrary to ubiquitin, the SUMO 
pathway has only one E2 enzyme, namely UBC9 (Saitoh, Sparrow et al. 1998). The 
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SUMO protein is transferred from Sae2 to UBC9 and forms a thioester link with cys93 
of UBC9. Note that UBC9 contains a SIM (SUMO-interacting motif) domain capable of 
recognizing the SUMO protein. Also UBC9-SUMO complex is capable of substrate 
specificity through the consensus SUMOylation motif found on the target protein 
(Tatham, Jaffray et al. 2001). At this point, UBC9 can either directly transfer SUMO 
protein to its substrate or optionally in vivo this step may require the cooperation of an 
E3 ligase.  
 
 
Figure 1.3: Isopeptide link between SUMO and its target protein 
 
A certain number of E3 ligases have been identified for the SUMO pathway. They 
are believed to facilitate the formation of the isopeptide bond between the C-terminal 
SUMO protein and the acceptor’s lysine by forming a complex with UBC9 and the 
SUMO protein. E3 enzymes do not seem to form thioester linkage with SUMO, but 
function as scaffold proteins bringing UBC9-SUMO complex in close contact with the 
substrate. E3 ligases have two roles: i) enhance the SUMO conjugation, and ii) 
  
 
6
participate in the specificity of the substrate. Most of the identified E3 ligases are 
nuclear, although new studies have reported the existence of a mitochondrial SUMO E3 
(Braschi, Zunino et al. 2009). Examples of E3 ligases include PIAS family, HDAC4 and 
RanBP2 (Wilkinson and Henley 2010). 
 
1.1.2.2 SUMO deconjugation 
 
SUMO is removed from its substrate by a family of enzymes known as the sentrin-
specific proteases (SENPs). Seven SUMO-specific proteases have been identified in the 
human genome (Marcin Drag 2008), showing different specificities towards SUMO 
isoforms. SENPs are cysteine proteases and have two main enzymatic activities: 
endopeptidase and isopeptidase as described in Figure 1.4.  
 
Figure 1.4: Reactions catalyzed by SENPs. Adapted (Mukhopadhyay and Dasso 
2007) 
 
1.1.2.2.1 Endopeptidase activity 
 
Newly synthesized SUMO is in an immature form and prior to conjugation, it needs 
to be activated by SENPs (see Figure 1.2). The propeptide is cleaved by SENP to reveal 
the essential diglycine motif which is conserved among all ubiquitin-like proteins 
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(Mukhopadhyay and Dasso 2007). The free diglycine motif is essential for the 
conjugation reaction. 
 
1.1.2.2.2 Isopeptidase activity 
 
The second role of SENP is the cleavage of the isopeptide bond (Figure 1.3), which 
is formed between the target and the SUMO protein. Therefore not only do SENPs 
control the pool of available SUMO, but they are also responsible for the half life of the 
conjugated species (Mukhopadhyay and Dasso 2007). Moreover, SENPs also control the 
poly-SUMO chain formation, by hydrolyzing the SUMO-SUMO bond. Due to their 
central roles, SENPs are believed to be highly regulated. 
 
In summary the SUMO pathway is highly regulated, first by its conjugation using a 
cascade of enzymes comprising an E1, an E2 and multiple E3 enzymes, but also by its 
deconjugation pathway.  
 
1.1.2.3 Poly-SUMO chain formation 
 
The concept of a modifier being modified adds a new layer of complexity, but also 
provides versatility to protein function. The formation of poly-ubiquitin chains has been 
extensively studied and it became clear that a specific poly-Ub chain structure provides a 
specific biological outcome (Pickart and Fushman 2004). The wide array of 
ubiquitylation outcome can be explained by the diversity of ubiquitin chain structure: the 
chain length but most importantly the different cross linkages that could be formed. 
 
Poly-SUMO chain formations have not been extensively studied due to important 
technical limitations: the half life and low abundance of the SUMO conjugates, as well 
as the absence of fast and straightforward method for the identification of SUMOylation 
sites. So far, SUMO2/3 has been shown to form poly-SUMOylation sites in vivo 
(Tatham, Jaffray et al. 2001), through the internal K11 that lies in a consensus sequence 
that is missing in SUMO-1 (Matic, Van Hagen et al. 2008). Although SUMO-1 is also 
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incorporated into the SUMO2/3 chains, it can’t be further modified and seems to work 
as a capping modifier. However, in vitro SUMO-1 has been shown to form polymers 
through K7,16,17,37,39,46 (Cooper, Tatham et al. 2005; Pedrioli, Raught et al. 2006). It 
is important to note that in vitro conditions are artificial (high concentrations of E1 and 
E2, absence of SENPs or E3 ligase) and can introduce artifacts. 
  
1.1.3 Consensus sequence 
 
Through the use of known SUMOylation sites of RanGap1, PML, p53 and SP100 a 
SUMOylation acceptor motif has been identified as ψ-K-X-E/D (Rodriguez, Dargemont 
et al. 2001) (where K is the acceptor lysine and ψ is a hydrophobic residue). No 
consensus sequence has been identified for ubiquitylation that might be due in part to the 
presence of a single E2 enzyme for SUMO (namely UBC9) that recognizes the 
consensus sequence and can directly SUMOylate the target. In contrast, the ubiquitin 
pathway contains about 20 E2 ligases and hundreds of E3 ligases (Semple 2003).  
 
Although 75% of known SUMO substrates are modified at the ψ-K-X-E/D motif 
(Xue, Zhou et al. 2006), this proportion is probably overestimated. Recently, Matic et al 
have proposed a new consensus motif: the inverted motif (E/DxK) (Matic, Schimmel et 
al. 2010) that seems to be less common. 
 
Two extended motifs have been discovered PDSM and NDSM. PDSM is a 
SUMOylation motif (ψ-K-X-E/D-X-X-pS-P) where downstream phosphorylation 
enhances SUMOylation (Hietakangas, Anckar et al. 2006). NDSM is characterized by 
the presence of the core consensus sequence followed by negatively charged residues at 
the C-terminus of the acceptor lysine (Yang, Galanis et al. 2006). A hydrophobic cluster 
SUMOylation motif was identified on 16 sites and its presence seems to greatly increase 
the efficiency of SUMOylation (Matic, Schimmel et al. 2010).  The presence of a 
consensus is not indicative that the protein is modified. As revealed by crystal structure 
studies, the SUMOylation consensus sequence has been shown to be recognized 
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specifically by UBC9 when found in an unstructured region of a protein (Bernier-
Villamor, Sampson et al. 2002).  
 
Since 25% of known SUMOylation sites are non-consensus sites, the mechanism 
through which these substrates are recognized by UBC9 is still unknown. 
 
Because of the difficulty in identifying the SUMOylation site on a given potential 
substrate, in silico prediction tools that make use of consensus motifs have emerged such 
as SUMOsp (Xue, Zhou et al. 2006).  
 
1.1.4 Molecular consequences of SUMOylation 
 
Protein SUMOylation is associated with numerous cell functions. In contrast to 
ubiquitylation that is best known to target protein for degradation, it is not possible to 
predict the biological outcome of SUMOylation on a given target. As for other PTMs, 
SUMO has been shown to be implicated in diverse and multiple biological mechanisms: 
intracellular transport, regulation of transcription and protein degradation. In the present 
section, I will cover one of the most studied functions of SUMO: Promyelocytic 
Leukaemia Protein Nuclear Bodies (PML-NBs) regulation. 
 
Nuclear bodies (NBs) are discrete protein aggregates where PML functions as the 
main scaffold protein. NBs have been implicated in multiple cellular functions such as 
transcriptional regulation and apoptosis, they are highly dynamic and a large number of 
SUMOylated proteins lie within this structure (Van Damme, Laukens et al. 2010). 
Because they are associated with a high number of cellular disorders (Lallemand-
Breitenbach and de The 2010), multiple studies in the past years have been conducted in 
understanding the composition as well as the function of NBs. More than 50 different 
proteins have been shown to shuffle in and out of NBs (Reineke, Liu et al. 2009), and in 
order to gain a better understanding of these structures, great efforts were made to 
characterize the complex regulation of PML. NBs were proposed to act as SUMOylation 
platforms, since a high proportion of NBs’ proteins are either SUMOylated or contain a 
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SIM domain. Moreover, the SIM-SUMO interaction might account for protein 
recruitment into the NBs (Lallemand-Breitenbach and de The 2010).  
 
PML is essential to nuclear body formation and seems to be the main recruiter of all 
the components, although it mainly interacts indirectly with NB proteins. PML is highly 
regulated at the transcriptional level but also by post-translational modifications such as 
SUMOylation. PML has been shown to be modified by all SUMO paralogs  at K65,160 
and 490 (Kamitani, Nguyen et al. 1998; Ayaydin and Dasso 2004) and it contains a SIM 
domain. It has been shown that SUMOylation of PML promotes its subsequent 
ubiquitylation and subsequent degradation, and this process is enhanced by arsenic 
trioxide (As2O3), a drug that is used in treating APL (Lallemand-Breitenbach, Jeanne et 
al. 2008). 
 
1.2 Mass Spectrometry 
 
Mass spectrometry is an analytical technique used to determine the elemental 
composition, structural information as well as the amount of analyte. The mass 
spectrometer separates and measures gas-phase ion’s m/z (mass to charge ratio). Mass 
spectrometry qualitative and quantitative applications are diverse and numerous and the 
focus in this thesis will be on MS based proteomics. 
  
The mass spectrometer can only detect molecules that are ionized; therefore the first 
step is the ionization and the vaporization of the molecule. Once the ion is in the gas 
phase it is separated by the mass analyzer based on its m/z. The observed ion can then be 
fragmented in order to obtain structural information. Finally, the abundance of the 
separated ion is recorded by the detector. 
 
In a typical large scale proteomics experiment, the analyte is the peptide mixture. 
The general procedure usually starts with cells lysis and can be followed by sub-
proteome fractionation. The proteins of choice are then enzymatically digested into 
peptides, usually by trypsin. The peptides are then chromatographically separated based 
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on their charge and hydrophobicity and analyzed by MS/MS. The raw data (MS and 
MS/MS spectra) are submitted to database search engines and a list of peptides along 
with their PTMs is obtained. 
 
1.2.1 Ionization  
 
Mass spectrometry (MS) has long been used mainly to analyze small volatile organic 
molecules, mostly because of the limitations of the classical ionization systems: electron 
ionization (EI) and chemical ionization (CI). With the introduction of electrospray 
ionization, ESI (Fenn, Mann et al. 1989), and matrix-assisted laser desorption ionization, 
MALDI (Karas and Hillenkamp 1988), the mass spectrum of intact peptides and proteins 
could be obtained. ESI and MALDI both present two main characteristics that make it 
possible to analyze biomolecules: i) soft ionization that does not disrupt the molecule, 
and ii) vaporization of non-volatile compounds. 
 
One of ESI’s main advantages is the possibility of using MS coupled to a liquid 
chromatography (LC) system (Figure 1.5). The LC-MS combination represented two 
main challenges. First the removal of all the solvent coming from the LC, because the 
MS operates under vacuum, and  second, the production of gas-phase ions from the 
normally non-volatile LC’s analytes (Watson and Sparkman 2007). Thus, ESI became 
the most successful interface for LC/MS, as the majority of the solvent is evaporated. 
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Figure 1.5: Use of ESI in an LC-MS coupled instrument (adapted from (Steen and 
Mann 2004)) 
In ESI the droplets containing the analyte are formed after the solution has been 
forced through a very small capillary (20 μm internal diameter) in the presence of an 
electric field. The electric field is fundamental for the ionization, but also for the 
nebulization of the analyte solution into fine droplets. As the volatile solvent (water and 
acetonitrile mixture) evaporates from the droplets, the ratio of charge to droplet size 
increases leading to charge repulsion. This process ends with a coulombic explosion, 
where smaller droplets are produced and analyte ions are ejected. The droplets 
eventually desolvate completely after multiple cycles of coulombic explosions. ESI can 
be used in positive and negative modes, by switching the potential, but it is mostly used 
in positive mode, and ions that are produced are [M+H]+ type ions. Acidified solvents 
are used to promote the protonation of the analyte. Nano-ESI, a miniaturized version of 
ESI, has the advantage of consuming very little sample, and its uses low flow rates to 
increase the ionization efficiency (Karas, Bahr et al. 2000).  
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1.2.2 The Mass Analyzer 
 
The mass analyzers are used to separate ions by their mass-to-charge ratio. Because 
of their charges, the ions’ position and trajectory in gas phase can be manipulated with 
magnetic and electric fields (Watson and Sparkman 2007). The mass spectrometer 
operates in a reduced pressure environment. This vacuum is mandatory to maintain the 
focusing capability of the analyzer, as collision with neutral molecules will lead to ion 
diffusion. 
 
A diverse and versatile range of analyzers exists on the market, and the important 
characteristics are the resolving power and the mass range. Resolving power (R) is the 
capacity for an instrument to separate two peaks and is defined by the following 
equation. M is the m/z of the peak and Δm is the difference in m/z between two adjacent 
peaks: 
 
m
MR
Δ
=  
Equation 1: Resolving Power 
High resolution instruments have the advantage of performing accurate mass 
measurement, and therefore enable the determination of potential elemental formulae 
within specific mass tolerances. High mass accuracy is achieved when the instrument is 
capable of well separating neighboring peaks (Gross 2004). Note that an increase in 
resolution is usually made at the cost of the sensitivity. Mass accuracy is typically 
expressed in ppm (parts per million) which corresponds to the difference between the 
observed and calculated mass divided by the molecular mass of the analyte. Proteomic 
analysis takes advantage of high resolution instruments by reducing the false positive 
rate in peptide assignments (Mann and Kelleher 2008). For instance, an accuracy of +/- 
1ppm reduces by 99 % all possible peptide assignments compared to using nominal 
mass measurements (Zubarev, Hakansson et al. 1996). 
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1.2.2.1  The Orbitrap mass analyzer 
 
The mass analyzer used in this study is the LTQ-Orbitrap (Figure 1.6), a hybrid 
instrument comprising a linear ion trap combined with a high resolution orbital trap 
(Scigelova and Makarov 2006). This hybrid instrument contains two analyzers that can 
detect ions: the LTQ most commonly is used to generate tandem mass spectra (MS/MS) 
while the orbitrap detects all ions of the survey MS scan at high resolution. The linear 
ion trap or linear trap quadrupole (LTQ) are capable of generating MS and MS/MS at 
high sensitivity, but with low mass accuracy. In the Orbitrap mass analyzer, the ion 
oscillates around an electrode, resulting in a frequency which is a function of its m/z. 
The Orbitrap’s main advantage is high resolution (~100,000 at m/z 400) enabling high 
mass accuracy measurements (1-2ppm) (Scigelova and Makarov 2006) while the LTQ 
offers high speed and sensitivity. By using high resolution MS, it is possible to detect the 
isotopic pattern of a given ion. The isotopic pattern provides information about the 
charge state (z) of the ion. 
 
Figure 1.6: Peptides are ionized in the ESI and fragmented in either the LTQ or in 
the HCD collision cell. The Orbitrap is used to detect parent m/z (adapted from(Olsen, 
Schwartz et al. 2009)) 
The orbitrap is an ion trap, where ions are trapped around an electrode. It consists of 
2 electrodes (inner and outer) between which an electric potential is imposed. Because 
of their shape, the electric field is non-homogenous between the electrodes; leading the 
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ions to oscillate along the inner electrode (Watson and Sparkman 2007). These 
oscillations are m/z dependent and this feature of the orbitrap makes it a mass analyzer.  
 
This concept had existed for a long time, but the main challenge was to introduce 
ions in the orbitrap. The C trap was designed to focus ions before injecting them into 
small pockets and this process is coordinated with the increase in the electric field in the 
orbitrap (Watson and Sparkman 2007).  
 
1.2.2.2 Linear ion trap mass analyzer 
 
The linear ion trap (LIT) is composed of a linear quadrupole and its function is to 
trap ions, select those of interest and fragment them (Watson and Sparkman 2007). High 
potential is applied at the front and the end of the quadrupole thus enabling the trapping. 
A potential well is created and the ions are stored in defined boundaries. To achieve a 
scan, the ions are ejected sequentially by applying an RF voltage and once ejected, the 
ions hit the detector.  The ejection of the ion occurs when the RF voltage matches the 
frequency of the ion of interest which is m/z dependent (Gross 2004). The selection of a 
particular ion is achieved when all the ions of lower and higher m/z are ejected. When 
the ion of interest is isolated, collision induced dissociation can occur in the trap using 
helium gas, producing fragments that can be detected (Gross 2004).  
 
1.2.3 Tandem MS 
 
MS/MS also referred to as tandem MS enables the acquisition of product ion spectra 
from precursor ions selected by the first mass analyzer. The second mass analyzer is thus 
scanned to transmit in turn fragment ions generated in a collision cell located between 
the two mass analyzers. The MS/MS spectrum reveals further structural information 
about the molecule and is the basis for peptide sequencing. Different algorithms 
currently exist to search the experimental MS/MS spectra and correlate observed 
fragment ions against those predicted from peptide candidates derived from a protein 
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database. Peptide fragmentation can be achieved using various techniques; some of 
which will be reviewed in this chapter. 
 
Typically proteomics experiments involve the use of an LC-MS, and therefore ions 
are only observed at a given elution time in a short time window (30-60 s). Ideally all 
ions that are detected in a given MS scan should be fragmented and sequenced. Despite 
the short period for the acquisition of MS/MS spectra (~300 ms ns for CID), only a 
small fraction of all detected peptide ions can be sequenced in a given LC-MS/MS 
analysis. This method of collection is called data-dependent acquisition, where only a 
pre-selected number of the most intense ions are being selected for MS/MS (Mann, 
Hendrickson et al. 2001). 
 
1.2.3.1 CID 
 
CID (collision induced dissociation) is by far the most popular fragmentation 
technique in proteomics. In CID, ions are first accelerated by an electrical potential, and 
then made to collide with neutral gas molecules such as nitrogen or helium. The 
collision between the incoming precursor ions and the target gas converts kinetic into 
potential energy that is distributed into the different oscillators of the ions. Bonds that 
have the lowest energy requirements (typically the amide bond of peptides under low 
energy CID) will be dissociated first. This technique is optimal when the precursor is 
doubly or triply charged, leading to singly charged fragments. The preferred 
fragmentation for peptides occurs at the amide bond, yielding b and y type fragments 
(refer to Figure 1.7). By looking at the mass difference of neighboring peaks, each of 
which corresponds to the mass of an amino acid, it is possible to deduce the peptide 
sequence. In the LTQ-Orbitrap instrument the CID fragmentation occurs in the LTQ. 
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Figure 1.7: Nomenclature of fragment ions observed for the dissociation of peptide 
ions . Figure from: http://www.ionsource.com/tutorial/DeNovo/full_anno.htm 
 
1.2.3.2 ETD 
 
ETD (electron transfer dissociation) is a dissociation technique that is based on 
adding a low energy electron to a multiply charged species (Watson and Sparkman 
2007). The fragmentation is very specific to the N-Cα bond (Boersema, Mohammed et 
al. 2009) first converting the peptide to a radical and forming c and z type fragment ions 
(see Figure 1.7). As electron source, ETD employs a radical anion (Syka, Coon et al. 
2004) such as fluoranthene radical and the ETD-reaction is held in the LTQ. The 
fluoranthene has a low electron affinity; therefore it readily passes its electron to a 
peptide (Boersema, Mohammed et al. 2009). The main advantage of ETD is to fragment 
large peptides and those with labile PTMs (Syka, Coon et al. 2004). Contrary to CID, 
ETD gives best results with multiply charged species with z>2. 
  
1.2.3.3 HCD 
 
The fragmentation and detection in the ion trap is efficient and sensitive, however it 
lacks the mass resolution for the fragment ions and low m/z ions are not trapped (Olsen, 
Macek et al. 2007). In high energy collisional dissociation (HCD), the fragmentation 
occurs in an octopole collision cell located at the far end of the C-trap. The 
fragmentation mechanism and pattern is very similar to the LTQ CID fragmentation, 
leading to y and b ions. One advantage in HCD is the capability of detecting low m/z 
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fragments. Since the detection occurs in the Orbitrap, high mass resolution is obtained 
on the product-ion spectra. Consequently, high mass resolution on fragment ions leads to 
higher confidence on the peptide identity.  
 
1.2.4 Detectors 
 
The last component of the mass spectrometer is the detector. Once the ions are 
separated, it is the detector that measures their respective signal. In the Orbitrap two 
detectors are present: a dynode detector after the LTQ and the image current measured 
from the motion of ions cycling in theOrbitrap analyzer. The dynode detector amplifies 
the signal by increasing the difference in potential in multiple steps. Once the ion hits 
the first electrode, multiple electrons are emitted which then hit the next electrode and so 
on (Gross 2004). In the Orbitrap the ions oscillate around a central electrode and 
surrounding plates record the frequency of the current followed by a Fourier transform 
that converts the frequency into m/z data (Makarov 2000).  
 
The dynamic range is an important factor when considering the choice of a detector. 
The dynamic range is the ratio of the most intense peak over the least intense peak in the 
same spectrum (Gross 2004). In proteomics analysis the two main challenges are the 
sample complexity and the very high dynamic range of protein abundance in the cell. 
For comprehensive proteomic analysis, a high dynamic range is required; however, the 
present day dynamic range of 103-104 is insufficient to cover the entire proteome (Mann 
and Kelleher 2008). 
 
1.2.5 Database Searching 
 
Following a single LC-MS run of 70 minutes, the instrument acquires up to 20 000 
spectra. In a typical 2 condition proteomics experiment performed in this laboratory, 
about 800 000 spectra are generated. This large amount of data cannot be analyzed 
manually and computational methods have been developed to process the raw data.  
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The mass of the peptide is obtained from the MS while the tandem MS contains 
masses of fragments relevant to the sequence. It is possible to determine the peptide’s 
sequence by calculating the mass difference between fragments and this procedure is 
called de novo sequencing. However, often MS/MS spectrum will only contain partial 
information and the entire sequence cannot be determined. In the 1990’s, following 
genome sequencing, the peptide sequencing became a database-search problem. In 
nature, only a small number of combinations of amino acid sequence exists compared to 
all the possibilities when dealing with de novo sequencing. Nowadays, the most popular 
approach is through database searching, where MS and MS/MS scans are submitted to 
search engines such as MASCOT (Perkins, Pappin et al. 1999) or SEQUEST (Eng, 
McCormack et al. 1994). Thanks to the genome sequencing project, it is possible to 
virtually digest all the proteins present in an organism and create a peptide database. 
First, a database of peptides is generated for an entire genome, using the sequence of the 
proteins and the enzymatic cleavage rules (for instance, trypsin cuts at the N-terminus of 
lysine and arginine). The theoretical MS/MS spectrum for a specific fragmentation 
method is obtained for each of those peptides with different PTMs. The precursor mass 
(from the MS spectrum) and the fragment mass (from the MS/MS spectrum) of each 
theoretical peptide are compared to the experimental result. When submitting raw data to 
search engines, the first step is to use the peptide mass from the MS spectrum to obtain a 
list of all possible peptides with all allowed post-translational modifications respecting 
the enzyme cleavage rules that correspond to this mass within the allowed mass 
deviation. The second step is to generate mock MS/MS spectrum for those peptides, and 
a matching score is calculated for each every possibility. When a peptide is modified, 
the mass of the modified residue is considered when interpreting MS/MS spectrum.  The 
comparison is done based on the allowed mass deviation for the precursor and the 
fragments’ mass. For instance when acquiring data in the LTQ-Orbitrap the allowed 
mass deviation is around 15ppm for the precursor mass and 0.5Da for the fragments. 
Database-searching approaches can only be used for organisms’ whose genome is 
sequenced and for which all the theoretical peptides are known (Steen and Mann 2004).  
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Each candidate peptide that matches to the experimental spectrum is assigned a score 
and a rank (Figure 1.8). The score is based on the quality of the match, for instance the 
number of fragments that were matched. Therefore, the score is the main parameter that 
is used to discriminate between right and wrong assignments. MASCOT, a widely used 
search-engine, uses the MOWSE algorithm to evaluate the match between the peptide 
and the spectrum (Pappin, Hojrup et al. 1993). MASCOT uses a probability-based 
scoring where the probability that a given match occurs randomly is calculated and its 
negative logarithm used as the score. The higher the score, the lower the probability that 
a given match is a random event.  It is worth noting that the search engines assume 
modifications are unfragmentable during the CID or ETD process, which is true for 
small chemical modifications such as phosphorylation and acetylation; however this is 
not the case for the SUMO-modified peptide.  
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Figure 1.8: The MS/MS spectrum is compared against a theoretical MS/MS 
spectrum generated in silico. A score is given to each peptide based on the similarity of 
the two spectra. Adapted from (Nesvizhskii, Vitek et al. 2007). 
The matching between the theoretical and the experimental peptide’s MS/MS is not 
an ideal process and some errors occur (Elias and Gygi 2007). The low intensity of the 
precursor peptide, the poor quality of fragmentation, the fragmentation of two peptides 
in a single MS/MS all can lead to mistakes. In order to calculate the false discovery rate 
(FDR), the data is searched against a decoy database (Elias and Gygi 2007). The decoy 
database is created by reversing the protein sequences used in the database, and the 
MS/MS spectra are searched against a composite database: the forward and the reverse 
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database. At a given score cut-off, the FDR is calculated with the number of reverse-
database matched peptides and therefore gives an estimate of the probability that a given 
match is a false positive. 
Equation 2: Calculating the false discovery rate 
peptidesTotal
peptidesmatcheddatabasereverseFDR
#
#2100 −××=  
 
1.2.6 Quantitative Proteomics 
 
Until recently, MS-based proteomics was mostly a qualitative technique that resulted 
in a list of proteins found under a given condition. In order to gain better insight into the 
biological relevance of the proteins present, the relative abundance of the proteins and of 
their respective modifications is necessary (Schulze and Usadel 2010). MS is not 
inherently quantitative: the ion’s intensity not only depends on the ion’s abundance, but 
also on the chemical properties of the peptide (charge, length, amino acid composition, 
etc.) and its environment (salts present during ionization). Absolute quantification 
cannot be performed on a given peptide simply based on its intensity. As a result, most 
of the large-scale MS quantification approaches always involve a comparison between 
two or more samples. Comparisons can only be made based on the same specie (the 
same peptide with the same m/z) since different peptides have different ionization 
efficiencies. 
 
A typical experimental design compares two conditions: a stressed versus a control 
status. Different quantification strategies have been developed in recent years and are 
divided as label-free and stable-isotope-labeling approaches (Schulze and Usadel 2010). 
In this laboratory, a label-free approach has been developed based on the correlation of 
peptide coordinates (m/z, time charge, intensity) across replicates and conditions. 
ProteoProfile is an in-house label-free bioinformatics software that quantifies peptides 
and proteins across different samples. 
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ProteoProfile creates peptide maps from LC-MS raw data and then clusters maps 
from different sample sets. First it creates contour maps that include retention time, 
charge, intensity and m/z for all detection peptide ions (see Figure 1.9).  
 
 
 
 
Figure 1.9: Contour map created by Proteoprofile. Symbols circle, cross and 
triangles are represent singly, doubly and triply charged  species respectively, while the 
range of intensities is represented with color from dark red to yellow being the most 
intense. 
Once maps are created for each sample, ProteoProfile then clusters the different 
samples together by aligning maps using linear dynamic correlation. Since the overlap in 
MASCOT identification between two LC-MS/MS of the same sample is around 60% 
due to the random process of selection when using data-dependent acquisition, the ions 
are not aligned based on their MASCOT identification, but rather accordingly to their 
retention time, m/z as well as the surrounding environment. Mass accuracy becomes 
even more important when dealing with label free quantification, since the clustering 
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relies on mass accuracy. Therefore, high-mass resolution instruments made label-free 
quantification even more appealing in recent years (Schulze and Usadel 2010). 
 
1.3 SUMO MS based proteomics 
 
In this section, different enrichment techniques of SUMO-conjugated proteins and 
SUMO-modified peptides bearing the modification sites will be described, followed by 
spectral interpretation strategies. 
 
1.3.1 Enrichment of SUMOylated proteins 
 
In order to identify Ub/Ubl modified proteins and their sites, the need for an 
enrichment strategy became apparent due to the low abundance and high turnover of 
those species.  A strategy was successfully employed to identify ubiquitin-conjugated 
proteins and their modification sites in yeast: around 1000 potential conjugates and 100 
ubiquitylation sites were identified (Peng, Schwartz et al. 2003).  
 
 
Figure 1.10: Purification strategy of His-SUMO conjugated proteins using the Ni-
NTA pull down. Contaminants are identified using the WT control and the SUMO-
conjugated proteins are uniquely present in the His-SUMO sample. 
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The approach described in Figure 1.10 and developed by Gygy laboratory is based 
on the expression of His6-ubiquitin in yeast and its subsequent purification. His6-
ubiquitin-conjugated proteins are isolated using Ni-NTA (nickel nitriloacetic acid) resin 
in denaturing conditions. In parallel, a control sample (wild type) expressing no His6-Ub 
is purified in the same manner and the isolated proteins are the non-specific 
contaminants that bind the resin. The success of this proteomic study inspired multiple 
groups to study SUMO-conjugates in a similar manner in yeast and in mammals (Matic, 
Schimmel et al. 2010), (Blomster, Imanishi et al. 2010), (Wohlschlegel, Johnson et al. 
2004), (Wohlschlegel, Johnson et al. 2006). The denaturing conditions are extremely 
important, since they first assure the inactivity of SENPs, and secondly assure the 
exclusive purification of SUMO-conjugates proteins and not their associated proteins. 
The proteins that are uniquely identified in the His6-SUMO expressing strain are 
assumed to be bona fide SUMO substrates. Up to now hundreds of putative SUMO 
conjugated proteins have been identified. 
 
1.3.2 Enrichment strategies of SUMO-modified peptides 
 
Mass spectrometric analysis of SUMOylation sites is technically very challenging 
and only a few sites have been identified until recently (Wilson and Heaton 2008). The 
majority of identified SUMO targets are only putative targets and their modification 
sites are still unknown. The identification of the conjugation sites can be important in 
understanding the regulation of SUMOylation.  
 
The digestion of purified SUMO conjugates leads to a mixture of peptides, most of 
which do not contain the modification site. This mixture is too complex for efficient 
identification of the modification site. Since SUMO-modified proteins are very low in 
abundance, this is even more problematic. 
 
Secondly, following trypsin digestion, the modified peptide is a branched peptide 
that contains a large C-terminal SUMO sequence. The absence of arginine and lysine 
residues makes the chromatographic separation and the MS analysis challenging. 
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Different strategies have been designed to alleviate the MS interpretation and SUMO 
peptide enrichment. 
 
In order to purify SUMO1-modified peptides, Bloomster et al engineered the human 
SUMO-1 protein so that following LysC digestion, the resulting peptide contains two 
cysteines followed by an arginine on the SUMO1 moiety (Blomster, Imanishi et al. 
2010). The SUMO1-modified peptides are then enriched using thiopropyl sepharose 
beads that bind through disulfide linkage with the SUMO1-modified peptides. The 
peptides of interest are then released from the beads using trypsin digestion that leaves a 
di-glycine tag on the lysine. This method allowed the identification of 14 SUMOylation 
sites in HeLa cells (Blomster, Imanishi et al. 2010). However, this method presents 
several drawbacks, such as the difficulty of distinguishing SUMO1-modified from 
Ubiquitin-modified peptides. The second drawback is the possible enrichment of non-
SUMO1-modified peptides that contain cysteine residues. 
 
A second purification strategy was developed using an engineered SUMO2/3. A 
LysC resistant His-SUMO protein was engineered where all lysines residues were 
mutated to arginines (Matic, Schimmel et al. 2010). The first step involves a LysC 
digestion followed by the Ni-NTA enrichment of SUMO protein linked to Lys-C 
digested target peptide. Following the Ni-NTA enrichment, the mixture is digested by 
trypsin. Using this method, 103 SUMO-2/3 acceptor sites were recently identified in 
mammals (Matic, Schimmel et al. 2010). Since all lysine residues are substituted by 
arginine, this mutant SUMO2 cannot form polySUMOylation and thus changes the 
function of the corresponding protein. 
 
All modified peptide based enrichment strategies present a highly modified form of 
the SUMO protein and therefore can introduce some artifacts.  
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1.3.3 Stress-induced SUMOylation 
 
Numerous studies observed an accumulation of SUMO-conjugates upon cellular 
stress (Saitoh and Hinchey 2000; Kurepa, Walker et al. 2003; Bohren, Nadkarni et al. 
2004; Manza, Codreanu et al. 2004; Golebiowski, Matic et al. 2009). Various external 
stress such as heat shock, oxidative and genotoxic chemicals have been tested on the 
SUMO system in many cell types, and SUMO4 expression has only been reported in 
extreme stress conditions (Wei, Yang et al. 2008).This effect is mostly observed with 
SUMO2/3 conjugates, following stress, the free SUMO2/3 is highly conjugated (Saitoh 
and Hinchey 2000), however SUMO1 does not seem to be affected in the same manner.  
 
When exposed to arsenic trioxide, PML and PML-RARα are SUMOylated and 
subsequently degraded by the ubiquitin-proteasome system (Lallemand-Breitenbach, 
Jeanne et al. 2008). PML-RARα is a fusion protein expressed in APL (acute 
promyelocytic leukaemia) and As2O3 is an agent used to treat APL (Zhu, Chen et al. 
2002). 
 
1.3.4 Spectral interpretation strategies 
 
So far, the common strategy in identifying SUMOylation sites is through site-
directed mutagenesis of consensus site lysines. However, it has been shown that non-
consensus lysines can be SUMOylated as for E2-25K (Pichler, Knipscheer et al. 2005) 
and the opposite is also true: not all consensus site lysine are SUMOylated. In order to 
gain a better insight on the biological role of SUMOylation, the need for a new and 
unbiased strategy for SUMO site identification has become important in the last decade. 
Mass spectrometry is the method of choice in identifying the modification sites for 
numerous PTMs. 
 
Most PTMs, such as ubiquitylation, methylation or acetylation, do not fragment 
during the CID or the ETD process in the MS. As an example, phosphorylation sites can 
  
 
28
be readily identified using standard sequencing softwares by including phosphorylation 
as a variable modification and simply altering the fragment’s mass by the mass of the 
modification (Figure 1.11b). Following trypsin digestion, the large SUMO tags produce 
multiple fragments that lead to complex fragmentation patterns, and although this adds 
confidence to the identification of the SUMO moiety, the MS/MS spectra is highly 
complex (Figure 1.11c) and renders spectral interpretation by MASCOT more prone to 
errors. Currently, two softwares were developed to specifically address this issue: 
SUMmOn (Pedrioli, Raught et al. 2006) and ChopNSpice (Hsiao, Meulmeester et al. 
2009). SUMmOn algorithm was developed to interpret complex fragmentation patterns 
of PTMs such as SUMO (Pedrioli, Raught et al. 2006). The CID spectra are scanned for 
the specific fragments that originate from the modifier. SUMmOn calculates two scores 
one for the target peptide and one for the modification, and although this system seemed 
to be successful for in vitro by identifying RanGap SUMOylation site, no conclusive 
result has been observed in vivo on a large scale data sets.  
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Figure 1.11: Theoretical MS/MS CID spectra of a) unmodified peptide, b) phospho-
peptide and c) SUMO-modified peptide. Complex fragmentation pattern of SUMO-
peptide renders data interpretation difficult. From (Pedrioli, Raught et al. 2006). 
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The branched SUMO-modified peptides fragment in a manner similar to that of the 
linear peptide with a lysine missed cleavage and the SUMO moiety on the N-terminus 
(Hsiao, Meulmeester et al. 2009). Based on this observation, ChopNSpice algorithm was 
developed. A database is constructed where every possible lysine is modified by SUMO 
and the resulting peptide is linearized. The MS and MS/MS spectra are searched against 
the ChopNSpice generated database and using this strategy 18 SUMOylation sites were 
identified in vivo for SUMO-1 in HeLa cells (Hsiao, Meulmeester et al. 2009).  
 
Although new bioinformatics strategies are more suitable for studying SUMOylation 
by MS, further technological advances would be required to provide more 
comprehensive SUMOylome analyses.  
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1.4 Project’s goal   
 
SUMO are a group of ~10kDa proteins that form an isopeptide linkage with the ε 
amino group of the target lysine. SUMOylation is a post-translational modification 
required for cell viability (Johnson, Schwienhorst et al. 1997; Hayashi, Seki et al. 2002) 
and shares great similarity with ubiquitin (Bayer, Arndt et al. 1998). At present, around a 
hundred SUMO targets have been identified and the molecular consequences of protein 
SUMOylation in vivo such as reciprocity between  ubiquitylation and SUMOylation, 
degradation and transcription regulation are unpredictable (reviewed in (Geiss-
Friedlander and Melchior 2007)). This modification affects protein function in a diverse, 
complex and sometimes opposite way. 
 
Large scale proteomics studies have been successful in identifying a high number of 
potential SUMO targets (Li, Evdokimov et al. 2004; Vertegaal, Ogg et al. 2004; 
Wohlschlegel, Johnson et al. 2004; Denison, Rudner et al. 2005; Gocke, Yu et al. 2005; 
Ganesan, Kho et al. 2007; Flick and Kaiser 2009). However, SUMOylation site 
identification is still a challenge, due to the very low abundance of SUMO targets in vivo 
as well as its rapid turnover upon cell lysis. Until now, SUMOylation site identification 
has mainly relied on site-directed mutagenesis, a time-consuming and burdensome task. 
To get a better insight into the molecular function of SUMOylation and a confidence in 
the target’s identity, the number and the location of the exact site is essential. 
  
In this context, the goal of this project is to develop a large scale MS based method 
to identify SUMOylation targets and their respective sites. Because of the very low 
abundance of SUMOylated proteins in the cell, and its highly dynamic nature (Geiss-
Friedlander and Melchior 2007), the first part of this thesis will focus on target 
enrichment.   
 
Following trypsin digestion of SUMOylated proteins, the peptides containing the 
modification site are branched. The analysis of branched peptide by MS is very limited, 
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partly due to the complexity of the MS-MS spectrum and the absence of efficient 
sequencing software (Pedrioli, Raught et al. 2006; Hsiao, Meulmeester et al. 2009). 
Hence, the second goal of this project is based on the interpretation of SUMO peptide 
MS/MS spectra.  
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2.1  Abstract 
 
The small ubiquitin-related modifier (SUMO) represents a small group of proteins 
that are reversibly attached to protein substrates to modify their functions. The large-
scale identification of protein SUMOylation and their modification sites in mammalian 
cells represent a significant challenge due to the relatively small number of in vivo 
substrates and the dynamic nature of this modification. We report here a proteomics 
approach to selectively enrich and identify SUMO conjugates from human cells. 
HEK293 cells stably expressing the different SUMO paralogs containing a His6 tag and 
a strategically located tryptic cleavage site to facilitate the recovery, identification and 
the isolation of SUMOylated peptides by affinity enrichment and mass spectrometry. 
The formation of tryptic peptides with short SUMO remnants offer significant 
advantages in large-scale SUMOylome experiments by generating paralog-specific 
fragment ions following CID and ETD activation and facilitating the identification of 
modified peptides using conventional database search engines such as Mascot. For 
SUMO-3 extracts, we identified 205 unique protein substrates together with 17 precise 
SUMOylation sites present in 12 SUMO protein conjugates using single-step NTA 
enrichment. Amongst SUMOylated substrates we identified promyelocytic leukemia 
(PML) with three new sites (K380, K400 and K497). The combination of a sequential 
NTA and immunoaffinity enrichment enabled the identification of 3 SUMO-1 modified 
peptides on low abundance SUMO-1 substrates (RanGAP1, SAFB2 and PML).  Label-
free quantitative proteomics analyses on untreated and arsenic trioxide-treated cells 
revealed that all identified SUMOylated sites of PML for both SUMO-1 and SUMO-3 
were differentially SUMOylated upon stimulation. 
  
2.2 Introduction 
 
The small ubiquitin-like modifier (SUMO) proteins are structurally similar to 
ubiquitin although they share less than 20% sequence identity (Kerscher, Felberbaum et 
al. 2006).  Like ubiquitylation, protein SUMOylation is regulated by a cascade of 
reactions involving SUMO-activating enzymes (SAE1/SAE2), conjugating enzymes 
(Ubc9) and one of several SUMO-E3 ligases (e.g. PIAS1, PIAS3, PIASxα, PIASxβ, 
PIASy, RanBP2 and Pc2) that covalently attach SUMO to specific protein substrates 
(Guo, Yang et al. 2007; Hsiao, Meulmeester et al. 2009). SUMO proteins are expressed 
as an immature proform that comprise an invariant Gly-Gly motif followed by a C 
terminal stretch of variable length (2–11 amino acids). Removal of this C terminal 
extension by sentrin-specific proteases (SENPs) to expose the di-glycine motif is 
necessary for the conjugation of SUMO to protein targets. These SUMO proteases are 
able to cleave both a peptide bond during the formation of mature SUMO, and an 
isopeptide bond to deconjugate modified protein substrates (Mukhopadhyay and Dasso 
2007). This covalent modification arises from the formation of an isopeptide bond 
between the ε-amino group of a lysine within the protein substrate and the C-terminus 
carboxy group of the SUMO glycine residue. SUMO conjugation frequently occurs at 
the lysine residue within the consensus motif ψKxE (where ψ is an aliphatic residue and 
x any amino acid) that is recognized by Ubc9 (Bernier-Villamor, Sampson et al. 2002; 
Lin, Tatham et al. 2002). Recent studies have also identified a phosphorylation-
dependent motif (ΨKxExxpSP) (Hietakangas, Anckar et al. 2006) and a negatively 
charged amino-acid-dependent motif (Yang, Galanis et al. 2006), that harbor negative 
charges next to the basic SUMO consensus site to enhance protein SUMOylation. 
However, several other SUMOylated proteins including PCNA, E2-25K, Daxx, and 
USP25 are modified at non-consensus sites (Hoege, Pfander et al. 2002; Pichler, 
Knipscheer et al. 2005; Shen, Tatham et al. 2006). Whether these types of sites are rare 
exceptions or reflect the presence of other E2-conjugating enzymes is presently 
unknown.  
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In lower eukaryotes, a single SUMO gene is expressed (Smt3 in Saccharomyces 
cerevisiae), whereas in vertebrates three paralogs designated as SUMO-1, SUMO-2 and 
SUMO-3 are ubiquitously expressed in all tissues. The human genome also encodes a 
forth gene for SUMO-4 that seems to be uniquely expressed in the spleen, lymph nodes 
and kidney (Guo, Li et al. 2004). However, its role remains enigmatic, as its in vivo 
maturation into a conjugation-competent form still remains unclear (Owerbach, McKay 
et al. 2005). Interestingly, SUMO-2 and SUMO-3 share 97% sequence identity, and are 
expressed at much higher levels than SUMO-1, with which they only share about 50% 
identity (Kerscher, Felberbaum et al. 2006). Although SUMO paralogs use the same 
conjugation machinery and have partial overlapping subsets of target proteins, they 
respond differently to stress (Golebiowski, Matic et al. 2009) and can be distinguished 
by their ability to form self-modified polymers in vivo and in vitro (Tatham, Jaffray et al. 
2001; Matic, van Hagen et al. 2008).  SUMO-1 lacks a consensus modification site and 
does not form polySUMO-1 chains in vivo, although RanBP2 was reported to be 
hypermodified by SUMO-1 chains in vitro (Pichler, Gast et al. 2002). In contrast, 
SUMO-2 and SUMO-3 can form polymeric chains in vivo and in vitro through their 
consensus motif (Tatham, Jaffray et al. 2001), whereas SUMO-1 forms terminating 
chain on poly-SUMO-2 or poly-SUMO-3 conjugates (Matic, van Hagen et al. 2008). 
 
Protein SUMOylation is an essential cellular process conserved from yeast to 
mammals and plays an important role in the regulation of intracellular trafficking, cell 
cycle, DNA repair and replication, cell signaling and stress responses (Hay 2005; Bossis 
and Melchior 2006; Hsiao, Meulmeester et al. 2009). Protein SUMOylation imparts 
significant structural and conformational changes on the substrate proteins by masking 
and/or by conferring additional scaffolding surfaces for protein interactions.  At present, 
a few hundred protein substrates are known to be SUMOylated in vivo. These protein 
targets include regulators of gene expression (e.g. transcription factors, co-activators or 
repressors) as well as oncogenes and tumor suppressor genes, such as promyelocytic 
leukaemia (PML), Mdm2, c-Myb, c-Jun, and p53 whose misregulation leads to 
tumorigenesis and metastasis (Hoeller and Dikic 2009). There is growing evidences of 
cross-talk between protein SUMOylation and ubiquitylation processes (Denuc and 
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Marfany ; Schimmel, Larsen et al. 2008). Earlier reports indicated that SUMOylation 
can antagonize the ubiquitylation of NFκB (Desterro, Rodriguez et al. 1998) whereas 
recent data also suggest that SUMOylation can be a prerequisite for ubiquitylation and 
subsequent proteasome-dependent degradation. A case in point is the identification of 
RNF4, an E3 ubiquitin ligase that specifically recognizes and ubiquitinylates 
polySUMO-chains of PML (Lallemand-Breitenbach, Jeanne et al. 2008; Tatham, 
Geoffroy et al. 2008).  Interestingly, PML SUMOylation can also be enhanced using 
arsenic trioxide (As2O3), a therapeutic agent used for the treatment of acute 
promyelocytic leukemia (APL) (Zhu, Koken et al. 1997; Muller, Matunis et al. 1998; 
Lallemand-Breitenbach, Jeanne et al. 2008). 
 
The relatively low abundance of protein SUMOylation is a significant analytical 
challenge for the identification and quantitation of this modification in vivo. Recent 
reports have described the successful identification of SUMO protein candidates by 
enriching the small subset of SUMOylated proteins using cysteine-targeted purification 
(Blomster, Imanishi et al. 2010), tandem affinity tag with His6-SUMO proteins resistant 
to Lys C proteolysis (Matic, Schimmel et al. 2010), cells stably expressing His6-SUMO 
constructs (Tatham, Rodriguez et al. 2009) and quantifying their proportions using mass 
spectrometry (MS) and metabolic labelling in cell cultures (Vertegaal, Andersen et al. 
2006). In spite of these significant advances, the identification of SUMOylation sites by 
MS remains challenging due to their variable stoichiometry and the presence of long 
SUMO C-termini polypeptides that complicates the interpretation of the corresponding 
product ion spectra. Upon tryptic digestion, SUMOylated peptides contain a relatively 
long SUMO remnant chain (up to 32 amino acid for human SUMO-2,3) appended on the 
modified Lys side chain. In contrast to other protein modifications, the SUMO remnant 
chain gives rise to multiple fragment ions that overlap with those of the target peptide. 
Accordingly, standard database search engines tailored to identify linear peptides are 
generally not capable of assigning the correct sequence of the branched peptides due to 
the complex distribution of overlapping fragment ions. This limitation was also 
described in an earlier report by Wohlschlegel et al. who indicated that yeast Smt3 
mutant with an arginine at the 3rd residue from the C-terminus yielded tryptic peptides 
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identical to those of ubiquitin remnant and facilitated their identification using the 
database engine SEQUEST (Wohlschlegel, Johnson et al. 2006). To overcome some of 
these limitations, different database searching strategies including an automated 
recognition pattern tool (SUMmOn) (Pedrioli, Raught et al. 2006)  and  combined search 
engines (ChopNSpice) (Hsiao, Meulmeester et al. 2009) were developed to identify 
potential acceptor sites from MS/MS spectra of these large precursor ions.   
 
Here, we present a new approach to the large-scale identification of modified 
peptides and their conjugation sites using three separate HEK293 cell lines, each stably 
expressing a SUMO mutant protein that contain a His6 tag and a strategically located 
tryptic cleavage site enabling convenient affinity enrichment and MS analyses of distinct 
SUMO paralogs.  We introduced an Arg residue at the 6th position from the C-terminus 
to minimize structural changes with respect to the endogenous proteins. We confirmed 
the activity and functional properties of the His6-SUMO mutants using in vitro 
SUMOylation assays and immunofluorescence. We profiled the subcellular distribution 
of SUMOylated proteins in HEK293 cells and monitored the change in SUMOylation 
upon As2O3 treatment. MS analyses of NTA-enriched nuclear cell extracts from mock 
and His6-SUMO-1/3 mutant HEK293 cells enabled the identification of unique 
SUMOylated protein substrates and their modification sites, including three novel sites 
on the protein PML. The separation of His6-containing proteins selectively enriched the 
mutated SUMOylated proteins from the endogenous counterparts, though their presence 
in the original cell extracts did not interfere with these analyses. The 
immunoprecipitation permitted the selective isolation of SUMOylation site containing 
peptides.  Moreover, we measured the effect of As2O3 on target modification using 
label-free quantitative proteomics, and observed an increase in PML SUMOylation in 
nuclear extracts consistent with previous reports for both SUMO isoforms (Muller, 
Matunis et al. 1998; Lallemand-Breitenbach, Jeanne et al. 2008). The insertion of an Arg 
residue at the C-terminus of each SUMO paralog not only facilitated the identification of 
SUMOylated peptides via the observation of paralog-specific fragment ions, but also 
reduced the abundance and distribution of overlapping fragment ions observed in 
MS/MS spectra of peptides with long modified Lys side chain. In addition, the five 
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amino acid SUMO remnant formed during the tryptic digestion of SUMOylated proteins 
can also be used for immunoaffinity enrichment. The use of a combined NTA and 
immunoaffinity enrichment is demonstrated for the identification of SUMO-1 modified 
peptides.  
 
2.3 Experimental section 
 
Plasmids construction and generation of stable HEK293 cells expressing SUMO 
constructs.  
cDNA of His6-SUMO wt and His6-SUMO mutants were generated by PCR with the 
forward primer containing His6-tag, KpnI and NcoI restriction sites 
5’gacccaagcttggtaccatggctcatc 3’ and the reverse primers containing STOP codon, XhoI 
restriction site. The WT and SUMO mutant primer sequences were:  
  
SUMO-1 WT :   
Forward 5’ gacccaagcttggtaccatggctcatc 3’ 
Reverse 5’ ctaccgctcgagttaaccccccgtttgttcctgataaacttc 3’  
 
SUMO-1 mut :  
Forward 5’ gacccaagcttggtaccatggctcatc 3’ 
Reverse 5’ctaccgctcgagttaaccccccgtttgttcccgataaacttc 3’ 
 
SUMO-2 WT :  
Forward 5’ gacccaagcttggtaccatggctcatc 3’ 
Reverse 5’ctaccgctcgagttaacctcccgtctgctgttggaacacatc 3’ 
 
SUMO-2 mut :  
Forward 5’ gacccaagcttggtaccatggctcatc 3’ 
Reverse 5’ctaccgctcgagttaacctcccgtctgctgtcggaacacatc 3’ 
SUMO-3 WT :  
Forward 5’ gacccaagcttggtaccatggctcatc 3’ 
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Reverse 5’ctaccgctcgagttaacctcccgtctgctgctggaacacgtc 3’ 
 
SUMO-3 mut :  
Forward 5’ gacccaagcttggtaccatggctcatc 3’ 
Reverse 5’ctaccgctcgagttaacctcccgtctggttccggaacacgtc 3’ 
 
The different His6-SUMO constructs were generated by inserting cDNA SUMO 
paralogs in pCDNA3 or pET28b in KpnI/XhoI or NcoI/XhoI respectively. pcDNA3-
PMLIII and pCDNA3-PMLIII-YFP were used as described in Percherancier and al. 
(Percherancier, Germain-Desprez et al. 2009). HEK293 stably expressing SUMO were 
obtained by transfection with pcDNA SUMO constructs and subsequent neomycine 
selection (0.5 mg/ml).  PML III WT and a PML III 3K construct with mutations at K65, 
K160 and K490 were obtained as described previously (Percherancier, Germain-Desprez 
et al. 2009).  
 
As2O3 treatment and antibodies.  
As2O3 (Sigma) was prepared in 1M NaOH, then further diluted to 1µM in the growth 
medium, and cells were typically exposed for 4h unless otherwise specified. Rabbit 
polyclonal anti-SUMO-1 and polyclonal anti-PML antibodies were from Santa-Cruz, 
rabbit anti-SUMO-2/3 and chicken anti-mouse Alexa-Fluor 594-conjugated secondary 
antibody from Invitrogen, monoclonal anti- His6 
 antibody from Clontech. HRP-conjugate monoclonal anti-β-actin from Sigma, goat 
secondary antibodies HRP conjugates from Chemicon International. The TIF-1β 
antibody was a gift from Dr. M. Aubry (Université de Montréal). Other antibodies used 
in this study were histone H3 polyclonal antibody (Cell Signaling, cat. #9715), PARP1 
antibody (Clontech, cat. # 630210) and the lamin A/C polyclonal (Santa Cruz, #SC-
20681).  
 
Enrichment of SUMOylated proteins 
Cells stably expressing His6-SUMO (107 cells) were lysed in denaturing buffer A (6 
M guanidinium-HCl, 0.1 M NaH2PO4, 0.01 M Tris-HCl, pH 8, 10 mM β-
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mercaptoethanol), sonicated, centrifuged at 16 000g and incubated with 50 µL NTA 
agarose beads (Invitrogen) for 3 h (Tatham, Rodriguez et al. 2009). After washing in 
buffer A and five times in buffer B (8 M Urea, 0.1 M NaH2PO4, 0.01 M Tris-HCl, pH 
6.3, 10 mM β-mercaptoethanol), the beads  were eluted with 300 mM imidazole in 0.15 
M Tris-HCl, pH 6.7, 30 % Glycerol, 0.72 M β-mercaptoethanol. The eluates were 
subjected to 4-12 % NuPAGE Bis-Tris Gel (Invitrogen). 
 
Confocal microscopy 
HEK293 cells, transfected with pcDNA3-His6-SUMO and pcDNA3-PMLIII-YFP, 
were fixed in 4% paraformaldehyde for 10 min at 4°C and revealed by anti-His 
antibody, followed by Alexa-Fluor 594-conjugated antibody. Confocal images were 
obtained on a Leica TCS-NT/SP inverted confocal lasers scanning microscope using an 
Apochromat x 63/1.32 oil-immersion objective. Co-localization experiments were 
performed by overlaying images using the Leica Confocal Software LCS (Heidelberg, 
Germany). Excitation and emission filters for the different labelled dyes were as follows: 
YFP (green): λex: 488 nm, λem: 540/25 nm; Texas red (red): λex: 568 nm, λem: 610/30 
nm.  DAPI  λex: 405 nm, 10 % power.  
 
Recombinant His6-SUMO proteins production and purification 
E. Coli BL21 cells transformed with different pET28- His6-SUMO expressing 
vectors were induced with 1mM IPTG for 5 h. Cells were lysed in 20 mM phosphate 
buffer pH 7.6, 500 mM NaCl and 30 mM imidazole by successive liquid nitrogen and 
37°C bath, followed by sonication. After centrifugation, the supernatant was loaded on a 
5 ml NTA HiTrap Chelating HP column (GE Healthcare). The column was washed 
according to the manufacturer instructions, and the sample was eluted using an 
imidazole gradient of 50-500 mM. The fractions containing most of His6-SUMO 
recombinant protein were concentrated on ultra-centricon with a cut-off of 30 kDa 
(Millipore). 
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In vitro SUMOylation assay  
To the reaction buffer (20mM NH4CO3 pH 9, 20 mM NaCl, 0.5 mM DTT), 1 µg 
recombinant SUMO proteins, 0.5 µg of substrates E2-25K (Boston Biochem), GST-
RanGAP fragment 418-587 (Boston Biochem), or GST-PML fragment 485-495 (Biomol 
International), 0.1 µg SASE1/SAE2 heterodimer (Boston Biochem), 0.5 µg conjugating 
enzyme hUbC9 (Boston Biochem) were added with or without 5 mM Mg-ATP (Boston 
Biochem). After incubation at 37°C for 1 h, the reaction was stopped with 10 mM 
EDTA. The samples were analysed by immunoblot, coomassie staining or silver staining 
and MS. 
 
Cell fractionation and large scale purification of SUMOylated proteins 
HEK293 cells (108 cells/replicate), stably expressing His6-SUMO mutant, were 
lysed in hypotonic buffer (10 mM Tris-HCl pH 7.65, 1.5 mM MgCl2, 1mM DTT, 20 
mM N-Ethylmaleimide, proteases inhibitors) and centrifuged at 3000g. The supernatant 
constituted the cytoplasmic fraction. The pellet was resuspended in buffer A, sonicated, 
centrifuged at 16 000g and added to 500 µl NTA agarose beads for 3 h. After washing 
and elution steps as described above, an aliquot of the eluate was used for immunoblot 
and the rest (50-60 μg/replicate) for MS analyses. Proteins were reduced in 0.5 mM 
tris(2-carboxyethyl)phosphine (TCEP) (Pierce) for 20 min at 37°C and then alkylated in 
50 mM chloroacetamide (Sigma-Aldrich) for 20 min at 37°C. A solution of 50 mM 
dithiothreitol was added to the protein solution to react with excess chloroacetamide. 
Total protein amount was quantitated by Bradford protein assay. Proteins were digested 
in 50 mM ammonium bicarbonate with modified trypsin (Pierce) overnight (1:30, 
enzyme:substrate ratio) at 37 ºC under high agitation speed. The digest mixture was 
acidified with trifluoroacetic acid (TFA) and then desalted using a HLB cartridge 
(Waters) and then dried down by speed vac prior to MS analyses.  
 
Immunoaffinity enrichment of SUMOylated peptides  
NTA-enriched protein extracts of ~50 μg/replicate were reduced with tris(2-
carboxyethyl)phosphine (TCEP) (Pierce), alkylated by chloroacetamide (Sigma-Aldrich)  
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prior to tryptic digestion (1:30 enzyme:substrate, sequencing grade trypsin, Promega, 
Madison MI). Tryptic peptides were incubated overnight at 4˚C with the SUMO-specific 
monoclonal antibody (10:1, antibody:peptide digest). The antibody-antigen solutions 
were washed 3 times with 300 μL of TBS buffer and 3 times with 0.1 x TBS in a 10K 
Microcon centrifugal dialysis tube (Waters, Milford, MA) to remove non-specific 
binding peptides. SUMOylated peptides were subsequently eluted using 0.2 % formic 
acid and collected in the non-retained fraction of the centrifugal dialysis unit. Eluates 
were concentrated on a Speedvac, re-suspended in 3% ACN, 0.2% formic acid and 
subjected to mass spectrometry analysis.  
 
Mass Spectrometry 
All LC-MS/MS analyses were performed using an LTQ-Orbitrap Velos hybrid mass 
spectrometer with a nanoelectrospray ion source (ThermoFisher, San Jose, CA) coupled 
with an Eksigent nano-LC 2D pump (Dublin, CA). Peptides were separated on a 
Optiguard SCX trap column, 5 µm, 300Å, 0.5 ID x 23 mm (Optimize technologies, 
Oregon City, OR) and eluted on-line to a  360 μm ID x 4 mm, C18 trap column prior to 
separation on a 150 µm ID x 10 cm nano-LC column (Jupiter C18, 3 μm, 300 Å, 
Phenomex). Tryptic digests were loaded on the SCX trap and sequentially eluted using 
salt plugs of 0, 75, 250, 500, 1 and 2M ammonium acetate, pH 3.5.  After adsorption on 
the C18 precolumn, peptides were separated on the analytical column using a linear 
gradient of 5-40% acetonitrile (0.2% formic acid) in 53 min and a flow rate of 600 
nL/min. The conventional MS spectra (survey scan) were acquired in profile mode at a 
resolution of 60 000 at m/z 400. MS/MS spectra were acquired in the ion trap using 
collision-induced dissociation (CID) only or by combining CID and electron transfer 
dissociation (ETD) with supplemental activation mode in a decision tree data-dependent 
fashion (Swaney, McAlister et al. 2008) for multiply charged ions exceeding a threshold 
of 10000 counts. The lock mass option was not used. ETD activation was triggered for 
precursor ions m/z < 650 (3+), m/z<900 (4+) and m/z 950 (5+). For ETD, the precursor 
cation AGC target was set at 50,000, whereas a value of 100,000 was used for the 
fluoranthene anion population. Ion/ion reaction duration was fixed at 200 ms. The 
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dynamic exclusion of previously acquired precursor ions was enabled (repeat count 1, 
repeat duration: 30 s; exclusion duration 120 s).  
 
Orbitrap raw LC-MS data files were transformed into peptide maps using in-house 
peptide detection and clustering software (Marcantonio, Trost et al. 2008). Peptide maps 
belonging to one experiment were clustered and aligned using clustering parameters of 
Δm/z= 0.02 and +/- 2 min (wide), +/- 0.5 min (narrow). Peptide clusters were aligned 
with mascot identification files to assign sequence identity. 
 
Protein identification and bioinformatic analyses 
MS data were acquired using the Xcalibur software (version 2.0 SR1). Peak lists 
were then generated using the Mascot distiller software (version 2.1.1, Matrix science) 
and MS processing was achieved using the LCQ_plus_zoom script. Database searches 
were performed against a nonredundant IPI human database containing 150858 
sequences (version 3.54, released Jan 2009) using Mascot (version 2.1, Matrix Science, 
London, U.K.). A Mascot search against a concatenated target/decoy database consisting 
of a combined forward and reverse version of the IPI human database was performed to 
establish a cutoff score threshold of typically 25 for CID or ETD with a false-positive 
rate of less than 2% (p < 0.02). The error window for precursor and fragment ion mass 
values were set to 0.02 and 0.5 Da, respectively. The number of allowed missed 
cleavage sites for trypsin was set to 1 and phosphorylation (STY), oxidation (M), 
deamidation (NQ), carbamidomethylation (C) and SUMOylation (K) (GGTQE: SUMO-
1 or GGTQQ: SUMO-2 or GGTQN: SUMO-3) were selected as variable modifications. 
We also developed a Perl script that searched the mascot generic file (mgf) for 
the specific SUMO fragment ions (e.g. SUMO-1: m/z 240.1, 258.1, 341.1, 359.2; 
SUMO-3: m/z 243.1, 344.2; and neutral losses of SUMO remnants) to produce a subset 
mgf file containing all MS/MS spectra of potential SUMOylated peptide candidates. 
Potential SUMO peptide candidates were also obtained using ChopNSpice by generating 
a modified IPI human database containing the five amino acid SUMO-specific tag on 
each lysine residue (Hsiao, Meulmeester et al. 2009). Database searches using 
SUMmOn were performed using a custom software available from Dr. Brian Raught 
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(University Health Network, Toronto, Canada) (Pedrioli, Raught et al. 2006). Manual 
inspection of all MS/MS spectra for modified peptides was performed to validate 
assignments.  
 
2.4 Results 
 
To facilitate in vivo identification of SUMOylated proteins, we developed pcDNA-
His-SUMO expression vectors comprising strategically located mutations at the C-
terminus of each SUMO paralog (Figure 2.1a). These mutations confer important 
properties to the stably expressed protein products. First, His6-SUMO mutants with an 
Arg substitution introduce a convenient tryptic cleavage site on the side chain of 
modified Lys residues whereby individual paralog can be identified by mass-specific 
signature fragment ions. Second, the short five amino acid segment appended to the 
modified Lys residues (e.g. EQTGG for SUMO-1 mut, Figure 2.1a) result in fewer 
fragment ions from the Lys side chain, a property that favor the identification of 
SUMOylated peptides using conventional database search engines. An additional 
advantage of the short SUMO remnant is the availability of an epitope to which 
antibodies can be raised and used in large scale immunoaffinity experiments. In the 
context of this study, we devised an affinity enrichment strategy whereby SUMOylated 
proteins are first isolated under denaturing conditions using NTA columns prior to their 
tryptic digestion and subsequently enriched using immunoaffintity purification. Finally, 
the SUMO-modified peptides are identified by LC-MS/MS (Figure 2.1b). 
 
His6-SUMO mutants are functional and can be use to monitor protein SUMOylation 
in vitro and ex vivo 
To determine that site-directed mutagenesis did not impair the transfer of His6-
SUMO mutants by the SAE1/2-Ubc9 conjugation machinery, we conducted in vitro 
assays using well-established protein SUMOylation substrates. We compared the 
SUMOylation profiles of His6-SUMO-1/2/3 wild type (WT) and the corresponding 
mutants using RanGAP1 and the ubiquitin-conjugating enzyme E2 (E2-25K), two 
proteins that are SUMOylated ex vivo and in vitro (Matunis, Coutavas et al. 1996; 
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Pichler, Knipscheer et al. 2005). An intact E2-25K and a GST-tagged C-terminal 
RanGAP1 protein fragment (aa 418-587) were SUMOylated in vitro as described 
previously (Matunis, Coutavas et al. 1996; Rogers, Horvath et al. 2003) (Figure 2.2a). 
The silver stained gels of the corresponding reactions indicated that all His6-SUMO 
mutants showed conjugation efficiencies comparable to those of WT SUMO proteins. In 
the presence of ATP, almost all protein substrates were converted to the SUMOylated 
RanGAP1 and E2-25K products. Interestingly, we observed polySUMOylated chains for 
all His6-SUMO mutants and WT proteins conjugated to RanGAP1, including SUMO-1 
that does not contain a ψKxE consensus motif. MS analyses of in vitro digestion 
products confirmed the SUMOylation of RanGAP1 for all SUMO paralogs on the 
residue corresponding to K524 (Annex I, supplementary Figure 2.1). PolySUMOylation 
was identified on K11 for His6-SUMO-2,3 mutants and their WT proteins.  We also 
observed SUMOylation of His6-SUMO-1 on sites K23, K37, K39 and K48, two of 
which (K37 and K39) were previously reported by Cooper et al. during in vitro 
experiments (Cooper, Tatham et al. 2005)  (Annex I, supplementary Figure 2.2).  In vitro 
SUMOylation analyses confirmed the covalent attachment of His6-SUMO-1-3 mutants 
to K14 of E2-25K (Figure 2.2b). Each His6-SUMO mutant was uniquely identified by 
specific fragment ions (b2*, b3*, b*2 - H2O, b*3 - H2O, etc...) arising from the cleavage of 
the SUMO side chain for precursor ions of m/z < 750 fragmented in the ion trap (1/3 
rule for fragment ion transmission).  The correlation of these unique fragment ions using 
extracted ion chromatograms facilitated the identification of potential SUMOylated 
peptides in complex tryptic digests. It is noteworthy that all SUMOylated proteins 
examined, including the fusion protein GST-PML485-495 were efficiently deSUMOylated 
by SENP1, thus confirming that the mutation site did not impair the enzymatic activity 
of the SUMO-isopeptidases (Annex I, supplementary Figure 2.3). 
 
We compared the ex vivo SUMOylation efficiencies of His6-SUMO mutants with 
their WT counterparts in HEK293 cells. We first examined the changes in SUMOylation 
of PML upon treatment with 1 μM As2O3 for 4 h. As2O3 is known to enhance the 
SUMOylation and the subsequent degradation of PML and the PML-RARα fusion 
proteins in APL cells (Zhu, Koken et al. 1997; Muller, Matunis et al. 1998; Lallemand-
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Breitenbach, Jeanne et al. 2008). Three SUMOylation sites within PML have been 
reported previously (Kamitani, Kito et al. 1998) though only K160 is required for 
As2O3-triggered degradation (Zhu, Koken et al. 1997; Lallemand-Breitenbach, Zhu et al. 
2001). Immunoblots showed increased polySUMOylation of PML for the His6-SUMO 
WT and mutants upon As2O3 treatment (Figure 2.3a, upper panel). The increase in PML 
SUMOylation was also accompanied by the depletion of the unmodified PML in both 
WT and mutant SUMO-3. The SUMOylation of PML was clearly evidenced in 
immunoblots from protein extracts purified using NTA columns (Figure 2.3a, bottom 
panel). It is noteworthy that PML showed an increase SUMOylation by SUMO-3 and 
SUMO-2 compared to SUMO-1, a situation that results in ubiquitin-dependent 
proteolytic degradation of PML (Stefan, Kirstin et al. 2008).  
 
     
PML is the organizer of subnuclear structures of 0.2-1.0 μm named PML nuclear 
bodies (NBs) that are not only present in most mammalian cell nuclei but also require 
SUMO for their formation. These subcellular foci are involved in the regulation of 
different cellular processes, including the induction of apoptosis and cellular senescence, 
inhibition of proliferation, maintenance of genomic stability and antiviral responses 
(Bernardi and Pandolfi 2007; Everett and Chelbi-Alix 2007). We examined the 
recruitment of His6-SUMO mutants and WT on NBs in HEK293 cells co-transfected by 
His6-SUMO and YFP-PML construct (Figure 2.3b).  Immunofluorescence staining of 
His6-SUMO mutants confirmed their co localization with YFP-PML in multiple and 
dense nuclear foci characteristics of PML NBs similar to that observed for His6-SUMO 
WT. In addition, As2O3 induced aggregation of SUMOylated PML in NBs for both His6-
SUMO-1 WT and mutant compared to untreated cells (Annex I, supplementary Figure 
2.4). Altogether, these experiments established that His6-SUMO mutants have functional 
characteristics similar to those of their WT counterparts. 
 
Subcellular distribution and induction of protein SUMOylation by As2O3  
To determine the global distribution of SUMOylated proteins, we performed 
subcellular fractionation to isolate cytosol and nuclear extracts from HEK293 cells 
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expressing WT and mutant His6-SUMO. Immunoblot analyses of these extracts using 
anti-His antibodies revealed that a higher proportion of SUMOylated proteins was found 
in nuclear fractions of cells expressing His6-SUMO-1 and His6-SUMO-3 mutants 
(Figure 2.4a, lanes 4 and 6). While polySUMOylation chains were observed for high 
molecular weight bands of these two paralogs, higher polymerization levels were noted 
for proteins modified with His6-SUMO-3 consistent with previous reports (Saitoh and 
Hinchey 2000). Interestingly, free His6-SUMO-1 and His6-SUMO-3 were more 
abundant in the cytosol compared to nuclear extracts (Figure 2.4a, lanes 3 and 5) as 
previously noted by Seeler et al (Seeler and Dejean 2003). It is noteworthy that anti-His 
immunoblots also revealed the presence of non-specific proteins in nuclear extracts of 
mock HEK293 cells (Figure 2.4a, lanes 1 and 2). MS analyses of these NTA-purified 
nuclear extracts (see below) identified several non-specific proteins including Forkhead 
box and homeobox proteins, POU domain transcription factors, Histidine triad 
nucleotide-binding proteins, that contain multi-His sequences and Zn metal-binding 
proteins known to bind to Ni2+ ions (Annex IV, CD-ROM supplementary Table I and 
2.2).   
 
Overall changes in protein SUMOylation were also evaluated in NTA-purified 
nuclear extracts from cells treated or not with As2O3 (Figure 2.4b). Enhanced protein 
SUMOylation was noted for both His6-SUMO-1 and His6-SUMO-3 mutants resulting in 
multiple band patterns of high molecular weight proteins for the corresponding SUMO-1 
and SUMO-2/3 immunoblots. It is noteworthy that multimerization can be obtained with 
mixed SUMO chains from endogenous and mutant proteins, the distribution of which 
depends on their relative proportion ex vivo. Interestingly, PML immunoblots of the 
same NTA-affinity purified extracts clearly showed an increased in the SUMOylation of 
endogenous PML upon As2O3 treatment (Figure 2.4b, upper panel). The corresponding 
banding pattern is almost superimposable to that of both SUMO-1 and SUMO-2/3 
immunoblots, suggesting that PML represents a primary SUMOylation substrate upon 
As2O3 treatment (Figure 2.4b, bottom panel).  Note that in the absence of As2O3, 
endogenous PML is barely detectable even when using longer exposure periods (data 
not shown). Although we have identified TIF-1β, Lamin A/C, Poly (ADP-ribose) 
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polymerase 1 (PARP1) and Histone H3 as modified proteins by SUMO (see below), we 
could not detect the SUMOylation of these endogenous proteins by immunoblots, 
presumably due to the low abundance of their SUMOylated counterparts in cell extracts 
and/or the inaccessibility of epitope for antibody binding (data not shown). Among all 
the proteins tested, only the endogenous PML showed enhanced SUMOylation in 
response to As2O3 (Figure 2.4b, bottom panel). 
 
Large scale identification of protein SUMOylation  
To identify SUMOylated proteins present in nuclear extracts, we performed large 
scale NTA-affinity purification experiments from HEK293 cells expressing His6-
SUMO-3 mutant exposed or not to As2O3. Similar experiments were also performed on 
mock HEK293 cells to identify proteins binding non-specifically to the NTA affinity 
column. We typically obtained 40-60 μg of NTA-purified proteins from 108 HEK293 
cells in any of the conditions and biological replicates examined. Proteins extracts 
following NTA purification (2 μg/injection) were subjected to MS analyses using a nano 
2D-LC system (SCX/C18) coupled to a LTQ-Orbitrap Velos instrument. Tandem mass 
spectra were acquired using CID and ETD in a decision tree manner to enhance the 
overall number of identification (Swaney, McAlister et al. 2008).  In total, we acquired 
more than 15,000 MS/MS spectra corresponding to 6282 unique peptides identified 
using Mascot database search engine. To reduce the number of ambiguous identification, 
we compared proteins that were identified by at least 2 peptides in each condition with a 
FDR of less than 2 %. By using these conservative selection criteria, we identified a total 
of 639 unique proteins, of which 232 proteins (36%) were common to all three different 
cell extracts (Figure 2.5a). Common proteins were assigned to non-specific binders co-
purified from NTA columns, and included proteins containing multi-His sequences and 
Zn metal-binding proteins.  It is noteworthy that some of these proteins such as E3 
SUMO-protein ligase RanBP2 (RanBP2), Zinc finger protein OZF, DNA topoisomerase 
1 (Top1) were previously reported to be SUMOylated, and their fortuitous isolation from 
mock HEK293 NTA extract could not definitively rule out their endogenous 
SUMOylation. More importantly, we identified 205 proteins specific to HEK293 
SUMO-3 mutant extracts (with and without As2O3) that comprised known SUMOylated 
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substrates such as PML, Transcription Intermediary Factor 1-beta (TIF-1β), PARP1, 
heterogeneous nuclear ribonucleoprotein isoform F (hnRNP F) and hnRNP C1/C2. A list 
of proteins found in protein extracts from each condition is provided in Annex IV CD-
ROM supplementary Table I. It should be noted that unambiguous assignment of 
SUMOylated proteins relies on the identification of tryptic peptides comprising the five 
amino acid SUMO remnant on the modified Lys residues, a situation that only applies to 
a smaller subset of the potential SUMOylated proteins (see below).  We also performed 
Gene Ontology analysis for terms associated with biological processes enriched in the 
HEK293 SUMO-1/3 mutant extracts using the software Protein ANalysis THrough 
Evolutionary Relationships, PANTHER (http://www.pantherdb.org/). These analyses 
revealed that potential SUMOylated targets were significantly enriched in proteins 
involved in chromatin remodeling, organelle organization, and nuclear transport 
(Supplementary Figure 2.5). 
 
The comparison of NTA-enriched protein extracts from cell expressing His6-tag 
SUMO-3 mutant enabled the identification of at least 205 SUMOylated protein 
candidates that were not detected in mock HEK293 cells. To identify the location of 
SUMOylation sites on protein substrates, we used Mascot, SUMmOn and ChopNSpice 
search engines. We also developed a script to make use of the specific SUMO fragment 
ions in order to retrieve all MS/MS spectra of potential SUMOylated peptide candidates 
(Experimental procedures). Altogether, we identified 17 unique SUMOylation sites on 
12 different protein substrates from these large-scale proteomics experiments (Table I). 
All MS/MS spectra were validated manually and comprised fragments characteristic of 
the SUMO-3 side chain (GGTQN).  A distribution of the number of identified residues 
according to the three different database search engines is provided in Annex IV CD-
ROM Supplementary Table III. We confirmed previously known SUMOylation sites on 
proteins such as PML (K490) and TIF-1β (K750, K779) and cross-link sites on SUMO-
2/3 (K11, K41 for SUMO-3 and K42 for SUMO-2). These analyses also revealed new 
SUMOylation sites on previously unreported nuclear substrates such as histone H3 
(K23), Lamin (K420), SAFB2 (K524), Rsf1 (K287), WIZ1 (K1523), and cross-link sites 
with SUMO-4 (K11) and ubiquitin (K11).     
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To profile proteins that showed differential regulation upon cell treatment with 
As2O3, we compared the abundance of peptide ions identified in digests of HEK293 
cells expressing His6-SUMO-3 mutant from control and stimulated cells.  The 
distribution of abundance for 6790 peptide ions is shown in the scatter plot of Figure 
2.5b, and indicated that more than 92 % of all ions showed less than 3-fold change in 
abundance upon cell stimulation. The most significant change was observed for PML, a 
protein that showed more than 15-fold increase upon As2O3 treatment. We obtained a 
sequence coverage of 43 % for this protein, and several PML tryptic peptides were 
found to be modified with SUMO-3 mutant.  For example, the product ion of the 
quadruply-protonated peptide ion (m/z 523.5) acquired using ETD fragmentation is 
shown in Figure 2.5c and confirmed the SUMOylation of the K490 residue. The MS/MS 
spectrum is dominated by c- and z-type fragment ions from the peptide backbone and by 
specific fragment ions arising from the cleavage of the SUMO-3 mutant side chain (e.g. 
c2*, c3*, c4*). As indicated in Figure 2.5b, the abundance of this peptide was increased 
in samples from cells treated with As2O3. Residue K490 is one of three known PML 
SUMOylation sites, the other two being K65 and K160 (Kamitani, Kito et al. 1998). 
However, we could not identify tryptic peptides harboring these two modified residues 
in any of the cell extracts examined, presumably due to the relatively large molecular 
weight and hydrophobicity of the corresponding peptides that precluded their successful 
separation by C18 chromatography.    
 
Our MS analyses also revealed the presence of three new PML SUMOylation sites at 
K380, K400 and K497.  Residues K380 and K400 were previously identified as sites of 
polyubiquitylation in response to As2O3 (Lallemand-Breitenbach, Jeanne et al. 2008). 
Site-directed mutagenesis indicated that mutation of K400 delayed but did not prevent 
PML ubiquitylation and its subsequent proteasome-mediated degradation (Lallemand-
Breitenbach, Jeanne et al. 2008). Residues K380 and K400 are located between the B 
box domains and the nuclear localization sequence (NLS) whereas K497 is next to the 
NLS of PML (Figure 2.6a). To confirm the identification of these new SUMOylation 
sites, we first examined possible site-specificities of different SUMO paralogs with 
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transfected PML and SUMOylation-site mutants thereof. We compared the ex vivo 
SUMOylation efficiency by each SUMO WT paralog in PMLIII WT and a PMLIII 3K 
mutant (K65R, K160R and K490R) in extracts from HEK293 cells co-transfected with 
the different PML and SUMO constructs (Figure 2.6b). Anti-PML immunoblots showed 
an increase in PMLIII WT SUMOylation by SUMO-2 and SUMO-3 when cells were 
exposed to As2O3, consistent with results presented in Figure 2.3a. This was clearly 
evidenced for the same protein extracts purified using NTA columns (Figure 2.6b, His 
pull down). It is noteworthy that similar experiments performed using more sensitive 
ECL immunoblots revealed the SUMOylation of PML by SUMO-1, but to a lower level 
than that observed for SUMO-2 and SUMO-3 (Annex I, supplementary Figure 2.6c). In 
all cases, PML showed significantly higher SUMOylation levels by SUMO-3 compared 
to other SUMO paralogs. In contrast, PMLIII 3K displayed one band in immunoblot 
analysis of extracts from cells co-transfected with PMLIII 3K and His6-SUMO WT 
treated or not with As2O3 (see input Figure 2.6b, upper right panel). Interestingly, NTA 
protein extracts of these samples indicated that residual SUMOylation of PMLIII 3K 
was observed with His-SUMO-3, and that this modification was enhanced upon As2O3 
treatment (see His pull down Figure 2.6b, middle right panel).  These experiments 
indicated that in the absence of the three known SUMOylation sites (K65, K160 and 
K490), PML is still SUMOylated, though the extent of this modification is significantly 
lower than that observed for PMLIII WT. The new sites identified could thus account for 
the remaining SUMOylation observed in PML.  
 
LC-MS/MS analyses of tryptic digests from NTA-purified protein extracts of 
HEK293 His6-SUMO-3 mutant cells identified three additional PML SUMOylation sites 
modulated by As2O3. The extracted ion chromatograms of multiply-charged ions 
corresponding to modified tryptic peptides at residues K490, K400 and K380 are 
presented in Figure 2.6c and indicated that all thee peptides are up-regulated by at least 
10-fold upon cell stimulation with As2O3. The tryptic peptide with SUMOylated K490 
and K497 residues was also increased in abundance upon As2O3 treatment (data not 
shown). The MS/MS spectra of precursor ions m/z 392.543+ and m/z 835.892+ showed 
abundant fragment ions from which the location of the modified residues could be 
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clearly established. It is noteworthy that the modified K380 and K400 residues are not 
harboring the consensus motif ψKxE/D.  We also validated these assignments using 
synthetic peptides baring the pentapeptide SUMO stub at the modified Lys residues. The 
MS/MS spectra of the corresponding peptides are shown as supplementary data (annex 
II and III) and yielded fragmentation patterns superimposable to those of the native 
peptides, thereby confirming two previously unknown SUMOylation sites on PML 
(Annex I, supplementary Figure 2.7).  
 
Identification of SUMOylated peptides using a dual affinity enrichment approach  
The expression of His6-SUMO mutants in HEK293 cells enabled a convenient 
approach to identify SUMOylated proteins and to distinguish them from proteins 
binding in a non-specific manner to the NTA column. The identification of modified 
residues in MS/MS experiments is also facilitated by the observation of fragment ions 
characteristic of SUMO remnants. While this approach enabled the identification of 
modified residues in a small subset representing less than 0.5 % of the entire peptide 
population, the detection of protein SUMOylation for paralogs expressed at a lower 
abundance (e.g. SUMO-1) remained a challenging task. Indeed, we could not identify 
any SUMO-1-modified tryptic peptides when similar 2DLC-MS/MS experiments were 
performed on NTA-enriched protein extracts from HEK293 His6-SUMO-1 mutant cells 
(data not shown).   
 
To facilitate the identification of SUMOylated residues from NTA protein extracts of 
HEK293 His6-SUMO-1 mutant cells, we raised monoclonal antibodies against the 
SUMO-1-specific GGTQE epitope. We optimized the binding and elution protocol using 
synthetic SUMOylated peptides from PML (K490) and E2 ligase (K14) spiked at 
different levels into HEK293 tryptic digests. Immunoaffinity binding experiments were 
performed overnight at 4˚C using a molar ratio of 10:1 antibody:antigen. Non-binding 
peptides were washed with TBS in a 10K centrifugal dialysis tube, and SUMOylated 
peptides were subsequently eluted using 0.2 % formic acid (Annex I, supplementary 
Figure 2.8a). Under optimized conditions, we obtained recovery yield of 30-70 % for 
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peptides spiked at 100-500 fmoles in a 9 ug tryptic digest of HEK293 (Annex I, 
supplementary Figure 2.8b).    
 
This dual affinity purification approach was applied to cell extracts for mock 
HEK293 and HEK293 His6-SUMO-1 mutant following cell stimulation with As2O3. In 
total, we identified 215 proteins unique to SUMO-1 extract in all three different extracts 
including transcription factors (Transcriptional repressor protein YY1, PML), DNA and 
RNA binding proteins (H2A, SAFB2).The complete protein list can be found in Annex 
IV, Supplementary Table II. The 2D-LC-MS/MS analysis of the tryptic digest following 
immunoaffinity purification enabled the identification of 4 SUMOylated tryptic peptides 
unique to the HEK293 His6-SUMO-1 mutant extract. It is noteworthy that 
approximately 48 % of the proteins identified following the immunoaffinity purification 
were assigned to non-specific binders since they were also observed in the mock 
HEK293 samples though their abundances varied significantly across sample sets. Our 
analyses identified 4 tryptic peptides baring the remnant SUMO-1 at the modified lysine 
residue, including peptides from PML (K490), RanGAP1 (K524) and SAFB2 (K294) 
(see Table II). A comparison of the contour map of m/z vs. time is shown in Figure 2.7a 
for a tryptic digest of a NTA-enriched protein extract before and after immunoaffinity 
enrichment. The contour map shows an expanded region of the PML tryptic peptide 
baring the modified K490 residue. The triply-protonated peptide ion at m/z 702.7 was 
hardly detectable in the NTA-enriched tryptic digest (Figure 2.7a, left panel) and was 
not sequenced by data dependent acquisition due to its low abundance (< 20000 counts). 
However, the same peptide ion was clearly evidenced following the dual affinity 
purification (Figure 2.7a, right panel), and yielded an MS/MS spectrum that was 
successfully assigned to corresponding modified peptide (see below). 
 
To profile proteins that showed differential SUMOylation upon cell treatment with 
As2O3, we compared the abundance of peptide ions following the dual affinity 
purification of digests from HEK293 cells expressing His-SUMO-1 mutant from control 
and stimulated cells. We monitored the abundance of 836 peptide ions identified in 
replicate analyses of HEK293 His SUMO-1 mutant cells with and without stimulation 
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with As2O3 (Annex I, supplementary Figure 2.9). Examples of extracted ion 
chromatograms are shown in Figure 2.7b for modified tryptic peptides of PML (K490), 
and RanGAP1 (K524). As observed, the PML tryptic peptide baring the SUMOylated 
K490 residue was only detected in cell extracts exposed to As2O3. This result is 
consistent with immunoblots shown in Figure 2.4b confirming the increased 
modification of PML by SUMO-1 upon As2O3 treatment. In contrast, RanGAP1, a well 
known SUMOylation target, did not show any significant changes in SUMOylation 
under the same conditions (Figure 2.7b, right panel). Confirmation of the sites of 
modification was obtained from the product ions spectra of the corresponding precursor 
ions (Figure 2.7c). All SUMOylated residues including SAFB2 (K294) displayed the 
consensus motif ψKxE/D. 
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2.5 Discussion 
 
The identification of SUMOylation sites on protein substrates represents an 
important analytical challenge owing to the relatively low stoichiometry and the 
dynamic nature of this modification. In mammalian cells, this difficulty is further 
exacerbated by the large peptide remnant of SUMO paralogs left on the modified lysine 
residue upon tryptic digestion. In this context, the construction of SUMO paralogs that 
comprise a His tag and a strategically located Arg residue on the C-terminus provide a 
convenient approach to enrich and identify short peptides baring the SUMO-specific 
remnant moieties. The judicious location of a C-terminus Arg residue was important in 
order to maintain the function of SUMO paralogs while minimizing structural changes 
compared to the endogenous proteins. Accordingly, plasmids were constructed with 
single base substitutions at the C-terminal end of SUMO paralogs to generate mature 
proteins with an Arg residue at the 6th position from the C-terminus, similar to that found 
in the yeast Smt3 protein.       
 
In vitro SUMOylation assays with well known protein substrates such as RanGAP1 
and E2-25K confirmed the functionality of the His6-SUMO mutants and their efficient 
transfer by the SAE1/2-Ubc9 conjugation machinery. MS analyses of the enzymatic 
products not only determined the expected modification sites on these substrates, but 
also identified sites of polySUMOylation for each paralog. In addition to the site K11 
previously reported on SUMO-2 and SUMO-3 proteins, we also identified 
polySUMOylation sites on SUMO-1 at K23, K37, K39 and K48, though the 
physiological relevance of SUMO-1 polymerization chains is presently unknown. 
Indeed, SUMO-1 which lacks the consensus motif ψKxE/D has not been reported to 
form polymeric chains although recent studies indicated that it can cap poly-SUMO-2,3 
chains (Martin, Wilkinson et al. 2007). Our analyses also indicated that MS/MS spectra 
of modified peptides afforded backbone sequence ions together with short SUMO-
specific fragment ions from CID and ETD activation that can be advantageously 
exploited to confirm SUMOylated peptides. The presence of paralog-specific fragment 
ions such as m/z 240.1 (b2*-H2O), 341. 2 (b3*-H2O) for SUMO-1 mutant and m/z 243.1 
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(b2*), 343.2 (b3*) for SUMO-3 mutant can be use for confirmation purposes as shown 
here or for targeted identification of these modified peptides via data-dependent 
acquisition. The relatively limited number of fragment ions originating from the 
modified Lys side chain also facilitated protein identification using common database 
search engines such as Mascot (Annex IV, Supplementary Table III).  
 
The subcellular localization of SUMOylated proteins using immunoblotting and 
immunofluorescence experiments revealed that a large proportion of substrates are 
nuclear, an observation that also account for the significant role of this modification in 
transcription, DNA repair, nuclear bodies and nucleocytoplasmic transport. This 
distribution is partly attributed to the enrichment of SUMO-modifying enzymes in this 
compartment, although a sizable number of substrates are also present in the cytoplasm, 
plasma membrane, mitochondria and endoplasmic reticulum (Geiss-Friedlander and 
Melchior 2007).   We performed large-scale proteomics analyses of nuclear protein 
extracts from mock and His6-SUMO-3 mutants HEK293 cells to identify the nature of 
SUMOylated substrates including those that could be regulated by As2O3. By using strict 
comparison criteria, we found more than 205 proteins unique to the His6-SUMO-3 
mutants HEK293 cells such as proteins involved in chromatin remodeling, organelle 
organization, and nuclear transport (Annex I, supplementary Figure 2.5). Following 
immunoprecipitation, 215 unique proteins were identified in SUMO-1 cells that were 
absent in the mock. Interestingly, we found several proteins involved in the regulation of 
ribosome biogenesis including hnRNP proteins, RNA helicases, and ribosomal subunits, 
suggesting that SUMO-3 modification may regulate the assembly of these 
macromolecular complexes. Recent reports indicated that several of these substrates 
were identified in nucleolus extracts and appeared to be regulated through the ubiquitin-
proteasome pathway, suggesting that SUMOylation may target unassembled ribosomal 
proteins for degradation (Matafora, D'Amato et al. 2009) (Lam, Lamond et al. 2007). 
 
Our proteomics analyses also enabled the identification of several new 
SUMOylation sites in proteins such as histone H3 (K23), Lamin (K420), SAFB2 
(K524), Rsf1 (K287), WIZ1 (K1523), and cross-link sites with SUMO-4 (K11) and 
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ubiquitin (K11).  Several of the modified proteins are involved in transcription such as 
TIF-1β, HSF4B and PML.  Of particular interest is PML, a protein that localize to NBs 
where it also acts as a tumor suppressor through the regulation of p53 response to 
oncogenic signals (Pampin, Simonin et al. 2006). Quantitative proteomics revealed that 
PML showed more than 15-fold increase in abundance upon cell stimulation with As2O3. 
In response to As2O3, PML is phosphorylated through the mitogen-activated protein 
kinase (MAPK) pathway leading to its transfer from the nucleoplasm to the nuclear 
matrix, and to an increase in PML SUMOylation and NBs size (Lallemand-Breitenbach, 
Zhu et al. 2001; Hayakawa and Privalsky 2004). SUMOylated PML recruits the RING-
domain-containing ubiquitin E3 ligase, RNF4, resulting in its degradation through the 
ubiquitin-proteasome pathway.  
 
Interestingly, a PMLIII 3K where all three known sites of SUMOylation were 
mutated to Arg is still transferred to the nuclear matrix but is resistant to As2O3-induced 
PML degradation (Lallemand-Breitenbach, Zhu et al. 2001). The exact mechanism by 
which PML is transferred to the nuclear matrix in a SUMO-independent manner upon 
As2O3 treatment is still unclear, but could involve its prior phosphorylation.  It is 
noteworthy that the SUMOylated forms of PML were barely detectable when total 
extracts from control and As2O3-treated cells expressing PMLIII 3K and SUMO 
paralogs were analyzed by immunoblot with anti-PML antibody ((Lallemand-
Breitenbach, Zhu et al. 2001) and Figure 2.6b). Furthermore, we observed that NTA 
enrichment of protein extracts revealed residual SUMOylation of PMLIII 3K by SUMO-
3 and that SUMOylation of PMLIII 3K by SUMO increased in response to As2O3. Our 
data demonstrated that As2O3-mediated SUMOylation of PMLIII can still occur at sites 
other than the three known residues K65, K160 and K490.  Detailed proteomics analyses 
enabled the unambiguously identification of K380, K400, and K497 as additional 
SUMOylation sites regulated by As2O3 treatment. Interestingly, two of these sites (K380 
and K400) were previously shown to be ubiquitylated in vitro (Tatham, Geoffroy et al. 
2008). Further investigations are required to determine the significance of these new 
sites on PML functions. 
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The insertion of a tryptic site close to the C-terminus of SUMO facilitates the 
MS/MS interpretation but also renders possible the immunoenrichment of SUMO 
modified peptides. Anti EQTGG (SUMO-1) monoclonal antibody was generated to 
purify SUMOylated peptides. Prior to the IP, the samples are desalted, since the 
antibody/antigen reaction is performed in native conditions. Sample were analyzed 
before (data not shown) and after the IP. No SUMOylation sites were identified prior to 
the second enrichment for SUMO-1. Detailed analysis of raw data, suggested that 
SUMO peptides are present in the sample prior to enrichment, but the presence of 
contaminant peptides impair their identification. DDA favors the sequencing of high 
abundance species, and SUMOylated peptides that are of significantly lower abundance 
are under represented in the population of sequenced peptides as illustrated in Figure 
2.7. The application of dual affinity purification enables the enrichment and 
identification of low abundance SUMO-1 modified peptides. We monitored the effect of 
As2O3 on SUMOylated proteins from HEK293 cells and observed the differential 
SUMOylation of PML K490 while RanGap K524 SUMOylation remained unaffected. 
Our mass spectrometry data suggest that As2O3 treatment primarily affect the 
SUMOylation of PML, an observation that was correlated by western blot data.  
 
The availability of functional SUMO mutants that can be stably express in human 
cells opens up new avenues for large-scale SUMOylome analyses. The enrichment of 
SUMOylated peptides can be achieved using single or dual affinity purification with 
NTA column or in combination with immunoaffinity to enriched SUMOylated peptides 
baring the SUMO remnant motif.  We anticipate that the combination of a dual affinity 
enrichment approach will yield a larger proportion of SUMOylated tryptic peptides than 
that achievable with NTA alone for SUMO-3. The presence of short paralog-specific 
peptide segment on the side chain of modified Lys residues provides characteristic 
fragment ions that facilitate the identification and confirmation of SUMOylated peptides 
from complex cell digests. These fragment ions can be used advantageously in the 
design of MS data-dependant experiments to target their identification more efficiently.  
While MS/MS spectra of these modified tryptic peptides contain spectral features 
specific to the SUMO remnants, database search of the corresponding peptides can be 
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efficiently achieved using conventional search engines like Mascot. The analytical 
advantages of the present approach and the possibility of conducting quantitative 
proteomics analyses will greatly facilitate large-scale experiments to unveil the complex 
regulation of protein SUMOylation. 
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Table I : List of confirmed SUMOylated peptides from NTA-enriched of nuclear proteins from HEK293 His6-SUMO-3 
mutant 
Proteins Site* Status# Function 
Histone 3.3  
Histone 4 
HSF4B  
 Lamin A/C  
PML 
 
RSF1  
 
SAFB2  
 
TRIM28  
 
WIZ1  
K24 
K13 
K288 
 K420 
K380,K400,K490,K4
97_   
 
K287 
 
K524 
 
K750, K779 
 
Unknown 
Unknown 
Unknown 
 Unknown 
Unknown/unknown/known/unknow
n (Kamitani, Kito et al. 1998) 
Unknown 
 
Unknown 
 
Known (Mascle, Germain-Desprez et 
al. 2007) 
Unknown 
Nucleosome assembly 
Nucleosome assembly 
DNA-binding; Binds HSE; regulates transcription 
Nuclear lamina 
Transcription factor 
 
Assembly of nucleosome by RSF chromatin-remodeling 
complex 
Binds to scaffold/matrix attachment region. Inhibit cell 
proliferation   
Forms a complex with a KRAB-domain TF and ↑ KRAB-
mediated repression  
Link EHMT1/2 to CTBP corepressor machinery 
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 Ubiquitin 
SUMO-2,3 
 
SUMO-4 
K1523 
 K11 
K42 
K11 
K11 
 Unknown 
Known (Cooper, Tatham et al. 
2005) 
Expected 
Known (Tatham, Jaffray et al. 
2001) 
 Cross-link  
Cross-link 
Cross-link 
Cross-link 
 
*Sites refer to protein sequence including initiating Met residue. 
#Status indicates whether or not identified sites were previously reported along with the corresponding 
reference.  
 
Table II :List of confirmed SUMOylated peptides from the immunoprecipitation of nuclear proteins from HEK293 
His6-SUMO-1 mutant 
Proteins Site* Status# Function 
RanGap 
PML 
SAFB2 
K524 
K490 
K294 
Known 
Known 
Known 
 GTPase activator of Ran protein. 
Probable transcription factor. 
Binds to the S/MAR of DNA. Inhibit cell proliferation. 
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Figure 2.1: Overview of proteomics approach to the identification of SUMOylated 
peptides. 
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Figure 2.2: In vitro SUMOylation assays of a) RanGAP (K524) and E2-ligase (K14). b) 
MS/MS confirmation of modified K14 in E2-25K for individual SUMO paralogs. 
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Figure 2.3 : Comparison of His-SUMO WT and mutants to SUMOylate PML 
and to colocalize within nuclear bodies. a) Immunoblots of input (upper panel) or 
His pull down (lower panel) of extracts from HEK293 cells, co-transfected with 
PML and WT or mutant SUMO, treated or not with As2O3. b) Immunofluorescence 
of HEK293 cells co-transfected with YFP-PML and His-SUMO WT or mutant 
revealed using anti-His antibody. 
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Figure 2.4: Immunoblots of NTA purified extracts from control HEK293 and HEK293-
His-SUMO cells.  a) Comparison of cytosol (C) and nuclear (N) extracts using anti-His 
antibody. b) Increased protein SUMOylation in response to As2O3 revealed using anti-
PML, anti-SUMO-1 and anti-SUMO-2/3 antibodies. 
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Figure 2.5: Mass spectrometry analyses of SUMOylated proteins from extracts of 
control HEK293 and HEK293 His6-SUMO-3 in As2O3-stimulated and non-stimulated 
cells. a) Venn diagram showing the overlapping distribution of proteins in each cell 
extract. Proteins identified with at least 2 peptides were considered for the comparison. 
b) Intensity distribution of peptide ions identified in the HEK293 His6-SUMO-3 in 
As2O3-stimulated and non-stimulated cells. The change in abundance of the PML tryptic 
peptide comprising the K490 residue is indicated on the scatter plot. c) MS/MS spectrum 
of precursor ion m/z 523.524+  using ETD fragmentation. Residues and c-type fragment 
ions characteristic of the SUMO-3 isopeptide bond are shown in red. 
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Figure 2.6: Identification of new SUMOylation sites in the protein promyelocytic 
leukemia (PML). a) Structure of PML III showing the protein domains and the location 
of known and novel SUMOylation sites. b)  Immunoblots of protein extracts from 
HEK293 WT and HEK293-His-SUMO cells before (input) and after NTA enrichment 
(His pull down) revealed using an anti-PML antibody. The coomassie-stained SDS-
PAGE gel is shown to compare sample loading.  c) Extracted ion chromatograms for 
m/z 523.524+, 392.543+ and m/z 835.892+ corresponding to modified K490, K401 and 
K380 PML tryptic peptides, respectively. d) MS/MS spectra of precursor ions m/z 
392.543+ and m/z 835.892+ obtained using ETD and CID activation, respectively. 
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Figure 2.7: Identification of proteins modified by SUMO-1 using a combined 
NTA/immunoaffinity enrichment approach. a) Contour profile showing a narrow region 
of the LC-MS analysis of tryptic peptides from NTA protein extract of HEK293-His-
SUMO-1 before and after immunoaffinity enrichment with monoclonal antibody 
directed against the (K-GGTQE) epitope. b) Extracted ion chromatograms for m/z 
702.73+ and m/z 903.83+ corresponding to modified tryptic peptides K490 from PML 
and K380 from SAFB2, respectively. c) MS/MS spectra of precursor ions m/z m/z 
702.73+ and m/z 903.83+ obtained using CID activation. 
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3.1 General Approach 
 
SUMO is a PTM that attaches proteins via an isopeptide linkage through its C-terminal 
glycine and the ε amino group of the target lysine. This modification is regulated by a 
specific set of conjugating and deconjugating enzymes (Ulrich 2008). 
 
SUMOylation has been implicated in numerous important processes and diseases 
(Geiss-Friedlander and Melchior 2007). The main goal of this study is to develop a double 
affinity approach to selectively isolate SUMO-modified peptides bearing the modification 
site; to identify SUMO-conjugates peptides in vivo by mass spectrometry; and finally, to 
understand the effect of arsenic trioxide on this modification and, more precisely, on PML. 
 
Through the use of HEK293 control cells or the stable expression of His-SUMO1/3 
mutants, His-SUMO conjugates were purified in denaturing conditions with Ni-NTA 
beads. This approach proved to be successful in earlier reports for the study of Ub/Ubl 
conjugates (Peng, Schwartz et al. 2003). The mutants that were engineered can be 
discriminated by MS, rendering data interpretation easier compared to their wild type 
counterparts due to their shorter tag. Finally, the specific subset of SUMO-conjugated 
peptides bearing the SUMO-stub following trypsin digestion can be selectively 
immunoenriched. 
 
3.2 In Vitro SUMOylation 
 
The in vitro SUMOylation of proteins has become an indispensable tool for studying 
the functionality of this modification. The main advantage of in vitro systems is that it 
greatly simplifies data interpretation: the presence of a single substrate, the absence of 
competing reactions on lysines such as ubiquitylation or acetylation, and the absence of 
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SENPs. The recombinant conjugating enzymes (SAE1/SAE2, UBC9) and His-SUMO 
mutant or wild type are mixed with the substrate of choice in presence of Mg-ATP. 
SUMOylation results by a shift of ~20kDa; the outcome can therefore be separated by 
SDS-PAGE and viewed by silver staining or western blot against the substrate or the 
desired SUMO isoform. A control reaction is performed in the absence of Mg-ATP. 
 
The in vitro SUMOylation reactions were conducted on numerous targets. Substrates 
bearing (RanGap) or not (E2-25K) the consensus motif were SUMOylated, and the results 
showed that all His-SUMO mutant isoforms exhibited a similar pattern to their wild type 
counterpart. Neither the His tag nor the mutation at the C-terminus of SUMO seems to 
interfere with the efficient recognition of conjugating enzymes, and the SUMOylation 
reaction is not impaired. The SUMOylation sites were also confirmed by mass 
spectrometry, and the peptides bearing the modification were detected, sequenced, and 
corresponded to the sites reported previously in the literature (Pichler, Knipscheer et al. 
2005; Blomster, Imanishi et al. 2010). 
 
SUMO-2/3 isoforms are known to form polySUMOylation chains in vivo and in vitro; 
however, the capacity of SUMO-1 to form polySUMOylation chains in vivo is still under 
investigation. Following the silver staining of the in vitro SUMO-1 reactions with E2-25K 
and RanGap in presence of ATP, it was possible to observe a banding pattern. We 
hypothesized that this pattern is probably due to polySUMO-1 chains, and this hypothesis 
was confirmed by mass spectrometry. Four polySUMOylation sites were detected and 
sequenced for SUMO-1: K23, K37, K39 and K48, two of which were previously observed 
by Cooper et al. (Cooper, Tatham et al. 2005), but none matched those identified by 
Pedrioli et al. (Pedrioli, Raught et al. 2006). It was intriguing to observe this discrepancy 
between different reports for the mapping of the SUMO1 polyconjugation sites in vitro. We 
concluded that this variability might be in part due to substrates used in different studies 
(different substrates might direct different poly-SUMO1 linkages). It is important to note 
that in vitro systems are artificial systems that are far from matching physiological 
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conditions, and that solvent exposed lysines could be artificially SUMOylated because of 
the high concentrations of conjugating enzymes. We concluded that although in vitro 
results can be a good tool in providing insight into the possible conjugation sites for the 
substrate of interest, one should always confirm the identified sites in vivo. However, we 
cannot rule out that this incongruity could also be due to the His-SUMO-1 mutant isoform 
we are using, which may have a slightly different 3D structure compared to its WT 
counterpart, thus rendering new lysines available for conjugation. Nonetheless, the 
consensus K11 poly-SUMO2/3 site that was observed in vitro when our mutant isoform 
was used agreed well with previous reports (Tatham, Jaffray et al. 2001). 
 
The modifier being modified adds a new layer of complexity, but also versatility in 
biological function. It has been reported that different polyubiquitin linkages lead to 
different physiological functions (Pickart and Fushman 2004). Supposing the same applies 
to SUMO not only will we need to identify the specific SUMOylation site on the target, but 
also the type of polySUMO chain formed. Since SUMOylation has multiple functions, it is 
possible that the versatility of SUMO modification is due to the heterogeneity of the 
polySUMO chain formed. The heterogeneity does not only come from the lysine that is 
used to form linkages, but also from the modifier. As previously reported, it is possible to 
observe chains where ubiquitin is connected to other ubiquitin-like proteins such as NEDD 
or SUMO (Ikeda and Dikic 2008). 
 
The need for a straightforward method in identifying SUMOylation sites in vivo 
became even more apparent due to the possible inconsistency that the in vitro conjugating 
system can introduce. 
 
Two opposing processes regulate SUMOylation in the cell: the conjugation and 
deconjugation reactions. In order to further assess the functionality of the mutant SUMO, in 
vitro deSUMOylation reactions were conducted using His-SUMO1 wild type and mutant. 
First, in vitro SUMOylation reactions were conducted in presence and absence of Mg-ATP. 
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The E1 activity requires Mg2+, the SUMOylation reaction is stopped with the addition of 
EDTA, a chelating agent that binds to Mg2+. Following SENP1 treatment, the band 
corresponding to E2-25K-SUMO and RanGap-SUMO is absent for both the wild type and 
the mutant SUMO1 (Annex I, Supplementary Figure 2.3). The mutation and the His tag on 
SUMO do not interfere with SENP1 recognition and cleavage. 
 
3.3 The His-SUMO Mutant Functionality in HEK293 Cells 
 
The sequence of SUMO protein has no tryptic cleavage site in the vicinity of the C-
terminus. Consequently, following trypsin digestion of a SUMOylated protein, 19 and 32 
amino acids tags are released respectively for the human SUMO-1 and SUMO2/3. These 
large peptides are low abundance, and in addition their MS/MS interpretation is highly 
complex. To circumvent those challenges, His-SUMO mutants were created with a trypsin 
cleavage site at the 6th position from the C-terminus. Following trypsin digestion, a 
characteristic 5 amino acid stub is released.  
 
In vivo functional assays by western blot and immunofluorescence were performed by 
F. Galisson to confirm the functionality of the mutant SUMOs. SUMO is known to localize 
in NBs or PML bodies (Kamitani, Kito et al. 1998). One of the most studied targets of 
SUMOylation is PML, mainly due to its role in APL (Lallemand-Breitenbach and de The 
2010)., Treatment with As2O3 triggers PML SUMOylation, which is subsequently 
ubiquitylated and then degraded (Zhang, Yan et al. 2010).  
 
The functionality of SUMO mutants was tested on PML in the presence and  absence of 
As2O3. Both the wild type and mutant SUMO show a similar pattern that consists in an 
increase in the MW corresponding to the mono- or polySUMO conjugated PML (Figure 
2.3). We observe the depletion of PML following As2O3 due to its subsequent 
ubiquitylation, which is consistent with previous reports (Zhu, Chen et al. 2002). 
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In the immunofluorescence experiment, briefly the goal was to visualize the effect of 
As2O3 on the distribution of PML and His-SUMO wild type and mutant isoforms. Both the 
mutant and the wild type SUMO colocalize with the YFP-PML into nuclear bodies as 
previously reported (Lallemand-Breitenbach and de The 2010). This further confirms the 
functionality of the mutants in vivo.  
 
3.4 Overexpression of His-SUMO Proteins in HEK293 Cells 
 
In order to facilitate SUMOylation site identification, the His-SUMO protein is 
overexpressed in HEK293 cells. The goal behind overexpression is to increase the level of 
endogenously low SUMO conjugates (Geiss-Friedlander and Melchior 2007). However, 
overexpressing SUMO can possibly lead to artifacts such as the SUMOylation of non-
SUMOylable lysines. Moreover, overexpressing proteins can also lead to aggregate 
formation and their subsequent degradation (Sullivan 2007 ). It has also been reported that 
overexpression might potentially lead to misfolding; but, SUMO is a small protein (11kDa) 
and immunofluorescence studies have shown its proper localization in NBs. As described 
previously, the immunofluorescence studies that were performed by F. Galisson on the 
transfected cells showed a pattern of SUMO localization that reflected the reported pattern 
observed in literature (Kamitani, Kito et al. 1998). 
 
There are multiple advantages in using HEK293 cells, notably the ease of transfection 
and growth for large-scale experiments. HEK293 are easily transfected through the use of 
calcium phosphate, an easy and inexpensive method. In large-scale experiments, up to 500 
million cells per condition are lysed, and HEK293 cells have the advantage of growing fast 
and easily. Despite this fact, HEK293 cells are highly transformed and there is controversy 
over which cell type they are (Shaw, Morse et al. 2002). 
 
In the present study, polyhistidine-tagged SUMOs are used: this enables the subsequent 
purification using nickel affinity columns. Previously, it has been shown that increasing the 
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number of tags on SUMO decreases the efficiency of conjugation (Hannich, Lewis et al. 
2005). In this study, it is assumed that the histidine tag will not alter the protein property. 
The polyhistidine tag did not interfere with the in vitro SUMOylation or deSUMOylation 
assays, indicating that the recognition by E1, E2 and the SENP is not impaired. Moreover, 
it has been shown that polyhistidine tags show little effect on protein structure (Carson, 
Johnson et al. 2007). Based on these considerations, this study was conducted on the 
assumption that the polyhistidine tag had little to no effect on SUMOylation. Nonetheless, 
the recognition by E3 enzymes has not been tested, and if one considers working with a 
specific E3 ligase using the His-SUMO construct, proper in vitro SUMOylation control 
assays should be carried out. 
 
In this study, we focused on SUMO-1 and SUMO-3 substrate identification. SUMO-2 
was excluded for two main reasons. Firstly, SUMO-2 and SUMO-3 are known to be highly 
homologous (95%), and therefore it is assumed that they have similar targets. Secondly, the 
CID fragmentation of SUMO-2 conjugated peptides leads to a highly abundant ion 
corresponding to a loss of water (-18). This loss is strongly privileged in CID and thus 
compromises the fragmentation of the peptide. As illustrated in Figure 2.2b, the SUMO-2 
mutant fragments are ∼5 times lower in intensity by comparison to SUMO-1 and SUMO-3. 
This renders the MS/MS interpretation and sequencing more challenging. 
 
Moreover, the transfected HEK293 cells co-express the His-SUMO mutant protein but 
also the endogenous SUMO. The parallel expression of both genes implies there is a 
competition between the two forms of SUMO for conjugation. To maximize the 
identification of SUMO conjugates, the sole expression of the His-SUMO mutant is 
preferred. Homologous recombination of the endogenous gene with the mutant SUMO is 
technically challenging.  
 
In summary, site identification has been difficult since SUMOylation is of very low 
abundance (Pedrioli, Raught et al. 2006). Overexpressing SUMO in HEK293 cells is a 
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good starting point for the study of SUMOylation, even though the conditions are not 
physiological.  
 
3.5 Subcellular Distribution of SUMO 
 
SUMO is mainly nuclear, although in recent years cytoplasmic targets have been 
identified (Geiss-Friedlander and Melchior 2007). To enrich the sample in SUMO 
conjugated proteins, cells were fractionated prior to lysis, and the cytoplasmic and nuclear 
fractions were analyzed by western blot. As observed in Figure 2.4a, SUMO conjugates are 
highly enriched in the nucleus compared to the cytoplasm for SUMO-1 and SUMO-3. 
However, free or unconjugated SUMO is more abundant in the cytoplasm. Suggesting that 
upon conjugation SUMOylated proteins are shuffled to the nucleus; consistent with 
previous reports showing SUMOylation to be important for nuclear transport (Rodriguez, 
Dargemont et al. 2001; Munirathinam and Kalyanasundaram 2008). 
 
The western blot signal of SUMO-2/3 is more important than that of SUMO-1. Two 
reasons might explain the higher signal for SUMO-2/3 by western blot: firstly, the higher 
level of SUMO-2/3 conjugates in the cell; secondly, that SUMO-2/3 is known to form 
polymeric chains in vivo, which is still under investigation for SUMO-1 (Tatham, Jaffray et 
al. 2001). However, we cannot rule out the possibility that the difference in western blot 
signal is mainly due to the formation of SUMO-2/3 polymeric chains, since western blot 
cannot differentiate between SUMO-conjugates or polySUMO chains. The mass 
spectrometry analysis identified no SUMO-1 conjugated peptides following the Ni-NTA 
(results not shown); while 19 SUMO-3 modified peptides were identified through the same 
approach. In conclusion, in HEK293 cells the SUMO-2/3 conjugates are in higher 
abundance compared to SUMO-1 conjugates as observed by western blot and mass 
spectrometry. 
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A successful enrichment method should i) enrich in SUMO targets, and ii) deplete in 
contaminant proteins. The first advantage of analyzing the nuclear fraction is the 
enrichment of SUMO conjugates as discussed earlier. The second is that the sample 
complexity is highly reduced. Indeed, about 25% of proteins in the cell are nuclear (Finn, 
Mistry et al. 2006); therefore if only the nuclear fraction is analyzed, the possible 
contamination by highly abundant cytoplasmic proteins is reduced. In fact, the presence of 
highly abundant proteins compromises the detection and the sequencing by mass 
spectrometry of low abundance proteins such as SUMO conjugates. In addition, the high 
abundance of the unconjugated His-SUMO in the cytoplasm could also compromise the 
nickel pull-down. Since free His-SUMO binds to the Ni-NTA column, free His-SUMO 
could compete with SUMOylated conjugates during the purification.  
  
The main disadvantage of limiting to nuclear proteins is that we do not gain a global 
understanding of SUMOylation. Therefore future studies should also be carried out on 
cytoplasmic fraction.  
 
3.6 Ni-NTA Enrichment 
 
The selective isolation of SUMO conjugates in HEK293 cells was performed using 
cells overexpressing His-SUMO1/3 and a control non-transfected HEK293 cell line. The 
nuclear extracts were lysed in denaturing conditions (6M guanidine) and the proteins were 
purified by affinity chromatography using Ni-NTA resin. The highly denaturing conditions 
minimize the copurification of proteins that are associated to SUMO conjugates. 
Furthermore, the denaturing conditions inactivate the SENPs present in the lysate. Other 
tag approaches could be used, such as HA, Myc or Flag tag. However, those approaches 
rely on antibody-antigen recognition, consequently, denaturing conditions cannot be used. 
 
Following metal affinity chromatography of nontransfected cells, a high signal 
representing the background is observed (Annex I, Supplementary Figure 2.6). About the 
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same number of proteins (∼400) were identified in the mock cells as in the His-SUMO 
transfected cell line. The contaminant proteins identified in the mock cells represent the 
background that is subtracted from the transfected cell line identifications. By analyzing the 
nature of the mock proteins, we identified three types of contaminants: i) highly abundant 
nuclear proteins such as the hnRNP; ii) metal-binding proteins such as zinc fingers that can 
also bind to nickel; and finally iii) proteins containing multiple histidines in their primary 
sequence such as Hox-A9. A major challenges in this type of study is to discriminate 
between background proteins and bona fide SUMO conjugates. In order to get a better 
insight into the nature of the background proteins following nickel pulldown, we suggest 
the creation of a repertoire of contaminant proteins as it was previously proposed for Tap 
tagging (Gingras, Aebersold et al. 2005).  
 
 
3.7 Digestion and Peptide Separation 
 
The vast majority of MS-based proteomics studies utilize trypsin to cleave proteins into 
more analyzable peptides (Olsen, Ong et al. 2004). Trypsin has the advantage of being 
highly specific to the C-terminus of arginines and lysines, active under a wide range of 
conditions, and of producing doubly charged peptides that are easily analyzed by CID 
(Olsen, Ong et al. 2004). The SUMO mutant was engineered to produce a 5 residue stub 
(EQTGG for SUMO-1) cross-linked to lysine following trypsin digestion. When the wild 
type SUMO-1 is digested a 19 amino acid stub is left on the acceptor lysine. However, it is 
also possible to obtain a small stub (QTGG) by digesting the wild type SUMO-1 with Glu-
C. Despite the small SUMO tag left following the digestion, Glu-C is much less efficient in 
producing MS-analyzable peptides, in fact Swaney et al. showed a 36% decrease in peptide 
identification when Glu-C is used in comparison to trypsin on total yeast extract (Swaney, 
Wenger et al. 2010).  
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Prior to MS/MS analysis and following tryptic digestion, the peptides are separated by 
MudPIT (Multidimensional Protein Identification Technology), a two-dimensional liquid 
chromatography technique. First, the peptides are separated by charge with the use of a 
strong cation exchange phase, followed by reverse phase separation on a C18 column. 
Cation exchange is used because peptides are positively charged following trypsin 
digestion. C18 columns are universally used for peptide separation in large scale 
experiments because they have a range of interaction with a broad variety of compounds. 
Following the SUMO-3 study, ∼6000 unique peptides were identified through this 
technique. Out of the 19 SUMO peptides identified, 8 contained a trypsin miscleavage 
adjacent to the SUMO-modified lysine. When there is a lysine or an arginine in the vicinity 
of the modified lysine, the SUMO modification seems to hinder trypsin from cleaving the 
peptide. Following this observation, we concluded that SUMO peptides are usually large 
due to the extra stub and multiple miscleavages, and thus hydrophobic. It is possible that 
some SUMO peptides were too hydrophobic to be analyzed by C18 chromatography. For 
instance, the SUMO peptide of PML K160 or K65 was not observed. Although the K160 
site is known to be SUMOylated and regulated by arsenic (Lallemand-Breitenbach, Jeanne 
et al. 2008), the corresponding tryptic peptide has not been detected due to its 
hydrophobicity. Using the sequence-specific retention calculator tool, we calculated the 
theoretical retention time of the SUMOylated K160 peptide to be ~53 minutes (Krokhin 
2006). The gradient stops at 55 minutes, therefore it is highly likely that the peptide never 
eluted. The identification of these hydrophobic peptides could possibly be improved by the 
use of a C5 column.  
 
SUMO-modified peptides are branched with two N-termini. This unique aspect could 
be exploited to selectively isolate this class of peptides using FAIMS (High-Field 
Asymmetric Waveform Ion Mobility Spectrometry), which separates ions according to 
their ion mobility. If branched peptides have characteristic ion mobility, they could be 
isolated from the rest of the mixture. 
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3.8 SUMO Peptide Identification by Mass Spectrometry 
 
3.8.1 Sample Complexity 
 
Out of 6282 peptides identified in the SUMO-3 MudPIT experiment, 19 were 
confirmed to be SUMO peptides. The very proportion of identified SUMO peptides is 
explained by two reasons. Firstly, SUMO peptides are of low abundance in the sample, and 
although they can be detected in the MS spectrum, they are not selected for MS/MS due to 
the presence of high-abundance co-eluting species. The data-dependent acquisition method 
privileges the sequencing of high-abundance species. Since the ion elutes over a ∼30 
second time window, the instrument cannot acquire MS/MS spectra for all ions detected 
and as a result, low-abundance ions are not sequenced. This is exemplified in the large 
scale SUMO-1 study. In Figure 2.7a the SUMO-1 conjugated peptide of K490 PML is 
present before and after the IP at the same level. However, the peptide was only identified 
following the IP because the sample complexity is reduced. It is thus likely that in the 
large-scale SUMO-3 experiment, numerous SUMOylated peptides co-eluted with highly 
abundant species and consequently were not sequenced.  
 
3.8.2 Spectral interpretation strategies 
 
The second main limitation in SUMO-peptide identification is the interpretation of the 
MS/MS spectrum. When the synthetic E2-25K K14 SUMO peptide is submitted to 
MASCOT, the search engine was not able to correctly sequence the peptide regardless the 
high quality of the MS/MS acquired (data not shown). Upon fragmentation SUMOylated 
peptide produces two ions series: one coming from the modification and one from the 
substrate peptide resulting in a mixed spectrum. It is expected that a certain proportion of 
SUMO modified peptide present in sample were not correctly assigned by MASCOT. 
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During a large scale experiment up to 100 000 MS/MS spectra are acquired, manual 
analysis of each MS/MS spectrum is impossible. 
 
In order to get around the high error rate of MASCOT, signature fragments and neutral 
losses specific to SUMO stub (for instance, EQTGG for SUMO-1) were used to validate 
the in vivo spectra identified by MASCOT. Each mutant isoform of SUMO leads to a 
characteristic fragmentation; in the case of mutant SUMO-1 fragments at m/z 258.1, 240.1 
and 341.1 are specific to the EQTGG sequence in CID. Theoretically, all SUMO-1 peptides 
upon CID fragmentation should have these signature fragments. The same phenomenon is 
observed with ETD. However, since the fragmentation is performed in the linear trap the 
fragments that are smaller than the 1/3 of the precursor’s m/z are not detected. In case 
where the precursor m/z was large (m/z > 3 times the m/z of signature fragment), the 
characteristic fragment ions are not detected. We expect this phenomenon to be important 
since SUMO peptides are large peptide.  
 
As observed by Jeram et al the fragmentation of the wild type SUMO modified peptide 
mainly leads to fragments coming from the SUMO chain and very little from the substrate 
peptide (Jeram, Srikumar et al. 2010). This phenomenon facilitates the identification of the 
modification, but unfortunately not of the substrate peptide and cannot reliably confirm the 
SUMOylation site. In contrast, the identification of mutant SUMO is facilitated. Because 
the mutant’s chain is smaller, the number of SUMO specific fragments is significantly 
reduced permitting the use of standard sequencing software. As a result, MASCOT was  the 
starting point in the interpretation of the MS/MS spectra. All SUMO modified peptides 
identified by MASCOT with a score >5 were analyzed manually. Those having a relatively 
good quality MS/MS spectrum and the presence of signature ions were considered as true 
positives. To minimize the false discovery rate the score cut off is set to 25 in standard 
proteomic studies. However because of MASCOT’s limitation in interpreting SUMO 
peptide spectrum, the score cut off is reduced. For instance, the H3 K24 SUMOylation site 
discovered in this study has a MASCO score of 13. Careful manual analysis of the 
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spectrum confirmed the identification. In some instances manual validation can also detect 
false positives. The SUMO peptide of RBM33 had a score of 48 with MASCOT, however 
after manual inspection, no SUMO specific neutral losses or signature ions were observed. 
Moreover, RBM33 SUMO modified peptide is also present in the negative control. In 
conclusion, manual validation of the MS/MS spectrum is a key step in the identification 
process. 
 
ChopNSpice is a database search tool that allows for the search of branched peptide by 
linearizing the peptide in silico (Hsiao, Meulmeester et al. 2009). Using this approach we 
identified one important site not observed using MASCOT: the K13 of H4 (Annex IV, 
Supplementary Table III). ChopNSpice database is 10X larger than the standard database, 
increasing the analysis time. Moreover, the linearization of the peptide introduces an 
artifact: in fact when the modification is located close to the C-terminus of the peptide, 
ChopnSpice performs poorly. For instance PML K497 (DAAVSK(SUMO)K) peptide was 
uniquely identified by MASCOT.  
 
Summon algorithm was also tested, but the identification rate was low (Annex IV, 
Supplementary Table III). Summon is optimal for large tags, such as the wild type SUMO. 
In contrast to the wild type SUMO, the mutant SUMO is shorter and therefore results in a 
fewer fragments. Summon limitation for shorter tags has been reported where it performed 
worst for the yeast isoform of SUMO, SMT3 (5 amino acid long tag) compared to human 
SUMO-1 (19 amino acid long tag) (Jeram, Srikumar et al. 2010).  
 
In conclusion, automated identification of SUMOylation sites is not yet optimal and 
manual validation is required. Further developments in search algorithms should enhance 
the sensitivity of SUMOylation site discovery.  
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3.8.3 Fragmentation methods  
 
Two different fragmentation techniques were used in the large scale SUMO-1 and 
SUMO-3 studies. CID and ETD were used in alternation in a decision tree manner based on 
the charge and the m/z of the precursor (Swaney, McAlister et al. 2008). CID is the 
traditional method mainly used for doubly charged species, and in recent years ETD has 
emerged as an important alternative fragmentation technique which is more optimal for 
highly charged species. It has been observed that SUMO modified peptide mainly exists in 
charge states > +3 due to their additional N-terminus. Although the majority of SUMO-3 
peptides were identified by both fragmentation modes or by CID alone, the K497 of PML 
and K420 of Lamin were uniquely identified using ETD (Annex IV, Supplementary Table 
III). By combining both modes the number of identification is increased as well as the 
confidence in those peptides that were sequenced by both modes. The main limitation of 
CID and ETD is the low mass resolution of fragment ions and the loss of low m/z 
fragments since which are not trapped in the LTQ. One way to obtain low m/z information 
and increase the mass resolution of product ion spectra is by HCD. Although HCD can 
bring multiple advantages, a high reduction in sensitivity has been reported (Dayon, 
Pasquarello et al. 2010). 
 
3.9 Immunoprecipitation and SUMO-1 Site Identification 
 
A monoclonal antibody was generated in mouse against a synthetic peptide containing a 
lysine residue modified with the SUMO-1 stub.14 different antibodies were generated and 
the best selected based on its specificity and selectivity against synthetic SUMO peptides of 
PML, RanGap and E2-25K. An immunoprecipitation assay was developed using a 
centrifugal filter device. Upon application of centrifugal force SUMOylated peptides bound 
to the antibody are retained in the upper chamber while the non specific peptides are 
collected in the bottom chamber (Annex I, Supplementary Figure 2.8a). Since most tryptic 
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peptides are <3kDa, they pass through the 10kDa filter unless bound to the anti-EQTGG 
antibody.  
 
The antibody was tested using synthetic peptides at varying concentrations in a tryptic 
digest of HEK293 cells at a fixed antibody concentration (Annex I, Supplementary Figure 
2.8b). The general trend observed is that the recovery increases with a decrease in SUMO 
peptide. At 5 fmol the recovery of E2-25K is the highest (75%), however the PML K490 
peptide was not detected at 5 fmol probably because it is below the limit of detection of this 
peptide. As the amount of antigen increases, while the antibody concentration stays 
constant, the ratio anyibody:SUMOylated peptide decreases and as a consequence the 
recovery drops. Because of the limited amount of antibody, the optimal antibody: antigen 
ratio for large scale studies is 10:1. At this ratio, the recovery is around ~30%. Based on 
these results and taking into account the limit of detection of most synthetic SUMO 
peptides (around 20 fmol), the SUMOylated peptides should be at least at 60 fmol in the 
initial in vivo extract prior to the IP to be detected in the elution sample. The analysis of the 
SUMO-1 Ni-NTA extract did not identify any SUMO peptide. However, following the 
immunoprecipitation 3 SUMOylated peptides of RanGap, PML and SAFB2 were detected. 
A large number of non SUMOylated peptides were present in the elution, in the SUMO-1 
As2O3 treated sample 408 peptides were identified by MASCOT and only 3 were 
SUMOylated. The low proportion of SUMOylatd peptide in the elution is probably due to 
multiple factors. First, the specificity of the antibody is poor because it was directed against 
a small sequence (EQTGG). We observed a high proportion of glutamic acid (E) containing 
peptides compared to the natural abundance. In fact, glutamic acid was found at 12.4% in 
our elution sample compared to its natural abundance of 6.3% (Betts and Russell 2003). 
This contrasts to alanine which was found at an abundance of 7.4% in our sample 
compared to 7.8% in nature (Betts and Russell 2003). Therefore, the antibody seems to 
preferentially bind to peptides rich in glutamic acid. Our hypothesis is that this sequence is 
too short to get a very specific immunogenic reaction in mice. In fact, the optimal epitope 
length is approximately 15 amino acids (Benjamin and Perdue 1996). The issue of low 
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antibody specificity could be resolved by using a more specific antigen. Xu et al. developed 
a similar antibody approach but with a very high specificity against the di-glycine tag 
specific to ubiquitin (Xu, Paige et al. 2010). In contrast to our approach, the antigen used 
was a protein with multiple di-glycines. As a result, the antibody recognized di-glycine 
tagged proteins and peptides with a very high specificity. Therefore, a protein antigen with 
multiple lysines all modified with EQTGG could increase the specificity of the antibody. 
 
A potent deSUMOylase inhibitor could increase the level of SUMO conjugates in the 
cell.  The ubiquitin studies use MG132, a proteosome inhibitor, resulting in an 
accumulation of ubiquitin conjugates in the cell prior to the lysis. No SENP specific 
inhibitor was developed to permit a similar accumulation of SUMO conjugates. Recently it 
was shown that MG132 treatment also increases the level of SUMO conjugates in the cell 
(Bailey and O'Hare 2005), probably because SUMO can be recognized by ubiquitin ligases 
and serve as a proteolytic targeting signal (Uzunova, Gottsche et al. 2007). Although a 
good proportion of SUMO conjugates accumulate upon MG132 treatment, it has been 
shown that SAFB2 SUMOylation decreases upon proteosome inhibition (Schimmel, Larsen 
et al. 2008). 
 
3.10  Effect of Arsenic Trioxide 
 
Western blot and mass spectrometry results showed an increase in SUMOylation of 
PML upon arsenic treatment as reported in literature (Stefan, Kirstin et al. 2008). Our MS 
method is reliable to identify and quantify SUMOylation in vivo. The advantage of mass 
spectrometry is the possibility to monitor the regulation of different site on the same protein 
(Figure 2.6c). A possible artifact of quantification is the presence of polySUMO chains. 
The polySUMOylated proteins are more efficiently enriched by Ni-NTA because of 
multiple poly histidine tags. 
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Arsenic trioxide is known to induce SUMOylation of PML and 3 of its conjugation 
sites are known (K65, 160 and 490) (Kamitani, Kito et al. 1998). PML-RαRα is a fusion 
protein expressed in APL which disrupts NBs, but As2O3 treatment promotes PML-RαRα 
degradation and restores NBs (Zhu, Koken et al. 1997). It is through K160 SUMOylation 
that arsenic promotes PML degradation (Lallemand-Breitenbach, Zhu et al. 2001). The 
increase in SUMOylation of PML is more important for SUMO-3 > SUMO-2 > SUMO-1 
by western blot. This pattern is explained by the fact that SUMO-3 and SUMO-2 form 
polySUMOylation chains in vivo. PML served as a positive control in our study since its 
regulation by arsenic is known.  One objective was to determine whenever PML is the sole 
target of over-SUMOylation following arsenic. To do so, data was processed by 
ProteoProfile: peptide identifications and abundances were clustered across different 
samples. Scatter plot of intensities with and without arsenic were constructed (for SUMO-3 
Figure 2.5b). In the SUMO-3 sample, the abundance of the vast majority of peptides 
identified (92%) was unaffected and the most significant change is for PML: 15 fold 
increase in SUMOylation in presence of As2O3. The K160 and K65 sites of PML were not 
identified in this study, probably due to their important size. The identification of large 
peptides is impaired due to chromatographical and MS/MS interpretation challenges.  The 
K490 PML SUMOylation site was identified for SUMO-1 and 3 and is induced by arsenic. 
PML seems to be the main target of arsenic and therefore we can speculate that As2O3 
treatment in APL is specific to PML and PML-RαRα. The scatter plot of SUMO-1, 
revealed that as expected RanGap K524 SUMO-peptides is not induced by arsenic, while 
PML K490 was only detected in presence of arsenic. In addition, the western blot anti-PML 
is super imposable to western blot anti-SUMO following Ni-NTA enrichment, further 
suggesting that the main target of arsenic is PML (Figure 2.4b). 
 
Studies performed on the PML 3K (where all SUMOylable lysines are mutated) 
showed residual SUMOylation (Figure 2.6b). The lower signal observed PML 3K 
SUMOylation suggests that the major modification sites are the known 3 sites. 
Nonetheless, these results suggested unknown sites in PML. The mass spectrometry 
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analysis of SUMO-3 extracts revealed the presence of 3 new sites (K380, 400 and 497) in 
PML all upregulated by arsenic (Figure 2.6c). The identity of PML K380 and K400 
SUMOylation was confirmed by synthesizing the corresponding peptides. The tandem 
spectra of the synthetic peptides gave a highly similar fragmentation pattern to the in vivo 
spectra confirming the MASCOT identifications (Annex I, Supplementary Figure 2.7). The 
tandem spectrum of K497 was not shown due to its complexity: in fact the peptide is also 
SUMOylated at K490 rendering interpretation more complex. The new sites identified are 
known ubiquitylation sites (Tatham, Geoffroy et al. 2008), possibly competing with 
ubiquitylation. This mechanism contrasts with the SUMOylation of K160 where the SUMO  
is itself ubiquitinated by RNF4 (Tatham, Geoffroy et al. 2008). 
 
In conclusion, the mass spectrometry experiment detected and identified known (PML 
K490) and new (PML K380, 400 and 497) SUMOylation sites in a quantitative fashion.  
 
3.11  Identified targets 
 
The GO term analysis of SUMO-3 and SUMO-1 protein identification sample revealed 
common biological processes (Annex I, Supplementary Figure 2.5): chromatin 
maintenance and establishment and nucleic acid metabolism consistent with previous 
studies (Matafora, D'Amato et al. 2009). SUMO is known to regulate transcription and 
genome stability (Eilebrecht, Smet-Nocca et al. 2010). Moreover, SUMO-1 has been 
shown to directly bind to DNA in a sequence independent fashion. For example 
conjugation to transcription regulators could possibly compete for the DNA binding 
(Eilebrecht, Smet-Nocca et al. 2010). SUMO modification may play a similar role when 
conjugated to SAFB2 hypothetically competing for DNA binding. Identified proteins found 
in the chromatin establishment and maintenance group are histones and two new 
SUMOylation sites in vivo for H3 and H4 were mapped. Core histones are known to be 
“master control switches” (Zheng and Hayes 2003). Histone sites identified are known 
acetylation sites suggesting a possible interplay between SUMOylation and acetylation. 
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The crosstalk of SUMOylation and acetylation on numerous targets was previously 
reported (Choudhary, Kumar et al. 2009; Wu and Chiang 2009). For instance, both 
SUMOylation and acetylation target the same lysines but have opposing roles for PLAG1 
and PLAGL2 (Zheng and Yang 2005). H4 SUMOylation has been previously suggested to 
be involved in transcriptional repression (Shiio and Eisenman 2003), and our study mapped 
the precise SUMOylation site of H4.  
 
The SAFB2 is proposed to be a tumor suppressor gene in breast cancer (Townson, 
Dobrzycka et al. 2003). SAFB2 binds to the Scaffold/matrix attachment regions of DNA, 
those regions are important in gene expression regulation. Two SUMOylation sites in vivo 
for SAFB2, interestingly the two sites differed: K294 for SUMO-1 and K524 for SUMO-3. 
This demonstrates the heterogeneity of SUMO1 versus SUMO2/3 targets. 
 
Lamin A, a highly modified protein and implicated in numerous diseases, is 
SUMOylated at K203 and the mutation of the consensus site is directly linked to familial 
dilated cardiomyopathy (Zhang and Sarge 2008). In this study, we mapped a new 
SUMOylation site for Lamin A/C the lysine 420. Further biological studies should be 
performed to understand the function of K420 SUMOylation.  
 
Finally, novel mixed polySUMO linkages were identified. We identified SUMO-4 
modified by SUMO-3 at K11. SUMO-4 is mainly expressed in kidney (Bohren, Nadkarni 
et al. 2004); therefore it is not surprising that SUMO-4 peptide is observed in HEK293 cells 
which are kidney cells. SUMO-4 contains a proline residue in the proximity of the 
diglycine tag that impedes its recognition by SENPs (Ulrich 2008). As a result, SUMO-4 
conjugation is still under debate, some studies suggesting its conjugation only under 
cellular stress (Wei, Yang et al. 2008). We found that SUMO-4 is cross- linked at K11, the 
same lysine where SUMO-2 and SUMO-3 were found to be modified. In conclusion, 
although SUMO-4 role as a modifier is debated, it can be itself modified by SUMO-3, and 
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it may have other biological role in the cell, probably through non-covalent interactions if it 
is not through covalent modification of targets.  
 
New polySUMOylation site were identified for SUMO-2 and SUMO-3 protein: K42 
and K41 respectively. These new sites were previously observed in vitro (Jeram, Srikumar 
et al. 2010), but there was no in vivo evidence. As previously demonstrated for ubiquitin 
(Pickart and Fushman 2004), different cross links could presumably lead to different 
physiological functions. These new sites might explain the diverse array of functions 
SUMO plays. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
109
 
3.12 References 
 
Bailey, D. and P. O'Hare (2005). "Comparison of the SUMO1 and ubiquitin conjugation 
pathways during the inhibition of proteasome activity with evidence of SUMO1 
recycling." Biochem J 392(Pt 2): 271-281. 
Benjamin, D. C. and S. S. Perdue (1996). "Site-Directed Mutagenesis in Epitope Mapping." 
Methods 9(3): 508-515. 
Betts, M. J. and R. B. Russell (2003). Amino Acid Properties and Consequences of 
Substitutions, John Wiley & Sons, Ltd. 
Blomster, H. A., S. Y. Imanishi, et al. (2010). "In vivo identification of sumoylation sites 
by a signature tag and cysteine-targeted affinity purification." J Biol Chem: -. 
Bohren, K. M., V. Nadkarni, et al. (2004). "A M55V polymorphism in a novel SUMO gene 
(SUMO-4) differentially activates heat shock transcription factors and is associated 
with susceptibility to type I diabetes mellitus." J Biol Chem 279(26): 27233-27238. 
Carson, M., D. H. Johnson, et al. (2007). "His-tag impact on structure." Acta 
Crystallographica Section D 63(3): 295-301. 
Choudhary, C., C. Kumar, et al. (2009). "Lysine acetylation targets protein complexes and 
co-regulates major cellular functions." Science 325(5942): 834-840. 
Cooper, H. J., M. H. Tatham, et al. (2005). "Fourier Transform Ion Cyclotron Resonance 
Mass Spectrometry for the Analysis of Small Ubiquitin-like Modifier (SUMO) 
  
 
110
Modification: Identification of Lysines in RanBP2 and SUMO Targeted for 
Modification during the E3 AutoSUMOylation Reaction." Analytical Chemistry 
77(19): 6310-6319. 
Dayon, L., C. Pasquarello, et al. (2010). "Combining low- and high-energy tandem mass 
spectra for optimized peptide quantification with isobaric tags." Journal of 
Proteomics 73(4): 769-777. 
Eilebrecht, S., C. Smet-Nocca, et al. (2010). "SUMO-1 possesses DNA binding activity." 
BMC Res Notes 3(1): 146. 
Finn, R. D., J. Mistry, et al. (2006). "Pfam: clans, web tools and services." Nucleic Acids 
Res(34 Database): D247 - 251. 
Geiss-Friedlander, R. and F. Melchior (2007). "Concepts in sumoylation: a decade on." Nat 
Rev Mol Cell Biol 8(12): 947-956. 
Gingras, A. C., R. Aebersold, et al. (2005). "Advances in protein complex analysis using 
mass spectrometry." J Physiol 563(Pt 1): 11-21. 
Hannich, J. T., A. Lewis, et al. (2005). "Defining the SUMO-modified proteome by 
multiple approaches in Saccharomyces cerevisiae." J Biol Chem 280(6): 4102-4110. 
Hsiao, H.-H., E. Meulmeester, et al. (2009). ""ChopNspice", a mass-spectrometric 
approach that allows identification of endogenous SUMO-conjugated peptides." 
Mol Cell Proteomics: M900087-MCP900200. 
  
 
111
Ikeda, F. and I. Dikic (2008). "Atypical ubiquitin chains: new molecular signals. 'Protein 
Modifications: Beyond the Usual Suspects' review series." EMBO Rep 9(6): 536-
542. 
Jeram, S. M., T. Srikumar, et al. (2010). "An improved SUMmOn-based methodology for 
the identification of ubiquitin and ubiquitin-like protein conjugation sites identifies 
novel ubiquitin-like protein chain linkages." Proteomics 10(2): 254-265. 
Kamitani, T., K. Kito, et al. (1998). "Characterization of a second member of the sentrin 
family of ubiquitin-like proteins." J Biol Chem 273(18): 11349-11353. 
Kamitani, T., K. Kito, et al. (1998). "Identification of Three Major Sentrinization Sites in 
PML." J Biol Chem 273(41): 26675-26682. 
Krokhin, O. V. (2006). "Sequence-Specific Retention Calculator. Algorithm for Peptide 
Retention Prediction in Ion-Pair RP-HPLC: Application to 300- and 100-Ã  Pore 
Size C18 Sorbents." Analytical Chemistry 78(22): 7785-7795. 
Lallemand-Breitenbach, V. and H. de The (2010). "PML nuclear bodies." Cold Spring 
Harb Perspect Biol 2(5): a000661. 
Lallemand-Breitenbach, V., M. Jeanne, et al. (2008). "Arsenic degrades PML or PML-
RAR[alpha] through a SUMO-triggered RNF4/ubiquitin-mediated pathway." Nat 
Cell Biol 10(5): 547-555. 
Lallemand-Breitenbach, V. r., J. Zhu, et al. (2001). "Role of Promyelocytic Leukemia 
(Pml) Sumolation in Nuclear Body Formation, 11s Proteasome Recruitment, and 
  
 
112
as2O3-Induced Pml or Pml/Retinoic Acid Receptor Î± Degradation." The Journal of 
Experimental Medicine 193(12): 1361-1372. 
Matafora, V., A. D'Amato, et al. (2009). "Proteomics analysis of nucleolar SUMO-1 target 
proteins upon proteasome inhibition." Mol Cell Proteomics 8(10): 2243-2255. 
Munirathinam, G. and R. Kalyanasundaram (2008). "Sumoylation is important for the 
nuclear transport and antioxidant function of the translationally controlled tumor 
protein." FASEB J. 22(1_MeetingAbstracts): 1026.1011-. 
Olsen, J. V., S.-E. Ong, et al. (2004). "Trypsin Cleaves Exclusively C-terminal to Arginine 
and Lysine Residues." Molecular & Cellular Proteomics 3(6): 608-614. 
Pedrioli, P. G. A., B. Raught, et al. (2006). "Automated identification of SUMOylation 
sites using mass spectrometry and SUMmOn pattern recognition software." Nat 
Meth 3(7): 533-539. 
Peng, J., D. Schwartz, et al. (2003). "A proteomics approach to understanding protein 
ubiquitination." Nat Biotech 21(8): 921-926. 
Pichler, A., P. Knipscheer, et al. (2005). "SUMO modification of the ubiquitin-conjugating 
enzyme E2-25K." Nat Struct Mol Biol 12(3): 264-269. 
Pickart, C. M. and D. Fushman (2004). "Polyubiquitin chains: polymeric protein signals." 
Current Opinion in Chemical Biology 8(6): 610-616. 
  
 
113
Rodriguez, M. S., C. Dargemont, et al. (2001). "SUMO-1 Conjugation in Vivo Requires 
Both a Consensus Modification Motif and Nuclear Targeting." J Biol Chem 
276(16): 12654-12659. 
Schimmel, J., K. M. Larsen, et al. (2008). "The ubiquitin-proteasome system is a key 
component of the SUMO-2/3 cycle." Mol Cell Proteomics 7(11): 2107-2122. 
Shaw, G., S. Morse, et al. (2002). "Preferential transformation of human neuronal cells by 
human adenoviruses and the origin of HEK 293 cells." FASEB J.: 01-0995fje. 
Shiio, Y. and R. N. Eisenman (2003). "Histone sumoylation is associated with 
transcriptional repression." Proc Natl Acad Sci U S A 100(23): 13225-13230. 
Stefan, R. W., K. Kirstin, et al. (2008). "Arsenic trioxide stimulates SUMO-2/3 
modification leading to RNF4-dependent proteolytic targeting of PML." FEBS 
letters 582(21): 3174-3178. 
Sullivan, K. F. (2007 ). Fluorescent Proteins, Elsevier Science. 
Swaney, D. L., G. C. McAlister, et al. (2008). "Decision tree-driven tandem mass 
spectrometry for shotgun proteomics." Nat Meth 5(11): 959-964. 
Swaney, D. L., C. D. Wenger, et al. (2010). "Value of Using Multiple Proteases for Large-
Scale Mass Spectrometry-Based Proteomics." Journal of Proteome Research 9(3): 
1323-1329. 
  
 
114
Tatham, M. H., M. C. Geoffroy, et al. (2008). "RNF4 is a poly-SUMO-specific E3 
ubiquitin ligase required for arsenic-induced PML degradation." Nat Cell Biol 
10(5): 538-546. 
Tatham, M. H., E. Jaffray, et al. (2001). "Polymeric Chains of SUMO-2 and SUMO-3 Are 
Conjugated to Protein Substrates by SAE1/SAE2 and Ubc9." J Biol Chem 276(38): 
35368-35374. 
Townson, S. M., K. M. Dobrzycka, et al. (2003). "SAFB2, a new scaffold attachment factor 
homolog and estrogen receptor corepressor." J Biol Chem 278(22): 20059-20068. 
Ulrich, H. D. (2008). "The Fast-Growing Business of SUMO Chains." Molecular Cell 
32(3): 301-305. 
Ulrich, H. D. (2008). The SUMO System: An Overview. 497: 3-16. 
Uzunova, K., K. Gottsche, et al. (2007). "Ubiquitin-dependent Proteolytic Control of 
SUMO Conjugates." J Biol Chem 282(47): 34167-34175. 
Wei, W., P. Yang, et al. (2008). "A stress-dependent SUMO4 sumoylation of its substrate 
proteins." Biochemical and Biophysical Research Communications 375(3): 454-
459. 
Wu, S.-Y. and C.-M. Chiang (2009). "Crosstalk between sumoylation and acetylation 
regulates p53-dependent chromatin transcription and DNA binding." EMBO J 
28(9): 1246-1259. 
  
 
115
Xu, G., J. S. Paige, et al. (2010). "Global analysis of lysine ubiquitination by ubiquitin 
remnant immunoaffinity profiling." Nat Biotechnol 28(8): 868-873. 
Zhang, X.-W., X.-J. Yan, et al. (2010). "Arsenic Trioxide Controls the Fate of the PML-
RAR{alpha} Oncoprotein by Directly Binding PML." Science 328(5975): 240-243. 
Zhang, Y. Q. and K. D. Sarge (2008). "Sumoylation regulates lamin A function and is lost 
in lamin A mutants associated with familial cardiomyopathies." J Cell Biol 182(1): 
35-39. 
Zheng, C. and J. J. Hayes (2003). "Structures and interactions of the core histone tail 
domains." Biopolymers 68(4): 539-546. 
Zheng, G. and Y.-C. Yang (2005). "Sumoylation and Acetylation Play Opposite Roles in 
the Transactivation of PLAG1 and PLAGL2." J Biol Chem 280(49): 40773-40781. 
Zhu, J., Z. Chen, et al. (2002). "How acute promyelocytic leukaemia revived arsenic." Nat 
Rev Cancer 2(9): 705-713. 
Zhu, J., M. H. M. Koken, et al. (1997). "Arsenic-induced PML targeting onto nuclear 
bodies: Implications for the treatment of acute promyelocytic leukemia." 
Proceedings of the National Academy of Sciences of the United States of America 
94(8): 3978-3983. 
  
 
 
 
 
4. Conclusion
 
 
 
117
 
4.1 The SUMO challenge 
 
Protein SUMOylation occurs on a wide variety of targets and has been implicated in 
numerous diseases (Geiss-Friedlander and Melchior 2007). The importance and versatility 
of SUMOylation in the cell is probably underestimated because of the difficulty in 
identifying SUMO substrates and more importantly their precise SUMOylation site.  
 
The need for a reliable, unbiased and fast technique for identifying targets and their 
attachment site became apparent. We developed a unique in vivo MS based quantitative 
approach that permitted the identification of 17 and 3 SUMOylation sites for SUMO-3 and 
SUMO-1 respectively. Our approach relies on the enrichment of SUMOylated proteins in a 
similar manner as described for ubiquitin by Peng et al. (Peng, Schwartz et al. 2003), 
followed by the immunoprecipitation of peptides bearing the modification site. A double 
affinity approach is necessary for studying SUMOylation because of its very low 
abundance and high turn-over in the cell.  The encouraging results obtained in this study as 
well as future ideas leads us to think that an even greater number of SUMOylation sites can 
be identified.  
  
We identified known and novel SUMOylation sites for SUMO-3 and SUMO-1. The 
identification of known sites confirmed that our technique, although not exhaustive, is 
reliable. The identification of unknown SUMoylation sites, even for highly studied protein 
such as PML and histones, illustrates the unbiased nature of mass spectrometry. All 
SUMOylation sites identified on PML were induced by arsenic. As of our knowledge, we 
are the first to report an MS based quantitative tool to study site specific SUMOylation. 
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4.2 Future Perspectives 
 
Our study focused on nuclear proteins, since a higher proportion of SUMO substrates is 
nuclear. Since recent reports highlighting the importance of SUMO outside the nucleus, we 
believe that the next large scale studies should also be performed on the cytoplasmic 
fraction. It will be interesting to evaluate the distribution of SUMO targets in different cell 
compartments.   However, the analysis of cytoplasmic fraction will present further 
challenges due to the higher complexity of the sample and the lower abundance of the 
analyte. To overcome this challenge, further fractionation and enrichment of the sample 
will be required. 
 
It is also important to increase the level of SUMO substrate in the cell; inhibiting the 
proteasome was shown to be successful (Matafora, D'Amato et al. 2009). Other agents are 
known to increase the level of SUMOylation such as oxidative stress and heat shocks.  
 
Finally, although multiple E3 ligases were identified recently for SUMOylation, the 
pairing between the specific ligase and its substrates is challenging. As future work, it is 
possible to use the tools that we developed to identify specific E3 ligase targets. For 
instance, PIAS is an important E3 ligase known to promote the SUMOylation of multiple 
key proteins such as STAT and p53 (Palvimo 2007), but it is believed that an even greater 
number of PIAS specific targets can be identified (Rytinki, Kaikkonen et al. 2009). In fact, 
PIAS functions are believed to be due to its capacity to act as SUMO E3 ligase. E3 specific 
study at the proteome level could further reveal the function of PIAS in the cell. 
 
We established the reliability of our method by clearly showing at multiple levels the 
agreement with previous reports. In addition, the discovery of unknown sites and its 
quantitative quality gives it multiple advantages as a leading tool in studying site specific 
SUMOylation. 
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Annex I: Supplementary Figures 2.1 -2.9 for Chapter 2 
(A Novel Proteomics Approach to Identify SUMOylated Proteins 
and their Modification Sites in Human Cells) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ii
 
a) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
iii
b) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Figure 2.1: MS analyses of in vitro digestion products of GST-RanGAP1 
(418-587) confirmed the SUMOylation site K524 for all SUMO paralogs. Tandem mass 
spectra of tryptic peptide LLVHMGLLKSEDK modified with (a) SUMO1, (b) SUMO3 
mutants using CID activation 
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a) 
MS/MS Fragmentation of LKESYCQR 
Found in In_vitro_E25K_Sumo1_06April2010_04.raw - IPI:IPI00916532- Tax_Id=9606 
Gene_Symbol=SUMO1 7 kDa protein  
 
Match to Query 5585: 1554.726668 from(778.370610,2+)  
 
Monoisotopic mass of neutral peptide Mr(calc): 1554.71 Variable modifications: K2 : SUMO EQTGG 
(K) (K) C6 : Carbamidomethyl (C) Ions Score: 21 Expect: 2.3 Matches (Bold Red): 22/70 fragment ions 
using 48 most intense peaks  
 
 
 
 
# b b++ b* b*++ b0 b0++ Seq. y y++ y* y*++ y0 y0++ #
1 114.09 57.55      L         8
2 714.38 357.69 697.35 349.18   K 1442.63 721.82 1425.61 713.31 1424.62 712.81 7
3 843.42 422.21 826.39 413.70 825.41 413.21 E 842.35 421.68 825.32 413.16 824.34 412.67 6
4 930.45 465.73 913.43 457.22 912.44 456.72 S 713.30 357.16 696.28 348.64 695.29 348.15 5
5 1093.52 547.26 1076.49 538.75 1075.51 538.26 Y 626.27 313.64 609.24 305.13   4
6 1253.55 627.28 1236.52 618.76 1235.54 618.27 C 463.21 232.11 446.18 223.59   3
7 1381.61 691.31 1364.58 682.79 1363.59 682.30 Q 303.18 152.09 286.15 143.58   2
8          R 175.12 88.06 158.09 79.55   1
  
 
 
 
 
 
Poly-SUMO-1 K48 
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b) 
MS/MS Fragmentation of VIGQDSSEIHFKVK 
Found in In_vitro_E25K_Sumo1_06April2010_06.raw - IPI:IPI00418254- Tax_Id=9606 
Gene_Symbol=SUMO1P1 LOC391257 protein  
 
Match to Query 6839: 2058.052448 from(1030.033500,2+)  
 
 
Monoisotopic mass of neutral peptide Mr(calc): 2058.04 Variable modifications: K12 : SUMO EQTGG 
(K) (K) Ions Score: 44 Expect: 0.029 Matches (Bold Red): 30/130 fragment ions using 42 most intense 
peaks  
 
# b b++ b* b*++ b0 b0++ Seq. y y++ y* y*++ y0 y0++ #
1 100.08 50.54      V         14
2 213.16 107.08      I 1959.98 980.49 1942.95 971.98 1941.97 971.49 13
3 270.18 135.59      G 1846.89 923.95 1829.87 915.44 1828.88 914.94 12
4 398.24 199.62 381.21 191.11   Q 1789.87 895.44 1772.84 886.93 1771.86 886.43 11
5 513.27 257.14 496.24 248.62 495.26 248.13 D 1661.81 831.41 1644.79 822.90 1643.80 822.40 10
6 600.30 300.65 583.27 292.14 582.29 291.65 S 1546.79 773.90 1529.76 765.38 1528.78 764.89 9
7 687.33 344.17 670.30 335.66 669.32 335.16 S 1459.75 730.38 1442.73 721.87 1441.74 721.38 8
8 816.37 408.69 799.35 400.18 798.36 399.69 E 1372.72 686.86 1355.70 678.35 1354.71 677.86 7
9 929.46 465.23 912.43 456.72 911.45 456.23 I 1243.68 622.34 1226.65 613.83   6
10 1066.52 533.76 1049.49 525.25 1048.51 524.76 H 1130.60 565.80 1113.57 557.29   5
11 1213.58 607.30 1196.56 598.78 1195.57 598.29 F 993.54 497.27 976.51 488.76   4
12 1813.87 907.44 1796.84 898.93 1795.86 898.43 K 846.47 423.74 829.44 415.22   3
13 1912.94 956.97 1895.91 948.46 1894.93 947.97 V 246.18 123.59 229.15 115.08   2
14          K 147.11 74.06 130.09 65.55   1
 
                
Poly-SUMO-1 K37 
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c) 
MS/MS Fragmentation of VKMTTHLK 
Found in In_vitro_E25K_Sumo1_06April2010_06.raw -  
 
Match to Query 5129: 1428.748068 from(715.381310,2+)  
 
Monoisotopic mass of neutral peptide Mr(calc): 1428.74 Variable modifications: K2 : SUMO EQTGG 
(K) (K) Ions Score: 23 Expect: 1.9 Matches (Bold Red): 10/70 fragment ions using 31 most intense 
peaks  
# b b++ b* b*++ b0 b0++ Seq. y y++ y* y*++ y0 y0++ #
1 100.08 50.54      V         8
2 700.36 350.68 683.34 342.17   K 1330.68 665.84 1313.65 657.33 1312.67 656.84 7
3 831.40 416.21 814.38 407.69   M 730.39 365.70 713.37 357.19 712.38 356.69 6
4 932.45 466.73 915.42 458.22 914.44 457.72 T 599.35 300.18 582.32 291.67 581.34 291.17 5
5 1033.50 517.25 1016.47 508.74 1015.49 508.25 T 498.30 249.66 481.28 241.14 480.29 240.65 4
6 1170.56 585.78 1153.53 577.27 1152.55 576.78 H 397.26 199.13 380.23 190.62   3
7 1283.64 642.32 1266.61 633.81 1265.63 633.32 L 260.20 130.60 243.17 122.09   2
8          K 147.11 74.06 130.09 65.55   1
  
 
Poly-SUMO-1 K39 
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d) 
MS/MS Fragmentation of EGEYIKLK 
Found in In_vitro_E225K_Sumo1_06April2010_04.raw -  
 
Match to Query 5228: 1450.736088 from(726.375320,2+)  
 
 
Monoisotopic mass of neutral peptide Mr(calc): 1450.73 Variable modifications: K6 : SUMO EQTGG 
(K) (K) Ions Score: 11 Expect: 27 Matches (Bold Red): 16/64 fragment ions using 42 most intense peaks  
# b b++ b* b*++ b0 b0++ Seq. y y++ y* y*++ y0 y0++ #
1 130.05 65.53    112.04 56.52 E         8
2 187.07 94.04    169.06 85.03 G 1322.70 661.85 1305.67 653.34 1304.68 652.85 7
3 316.11 158.56    298.10 149.56 E 1265.67 633.34 1248.65 624.83 1247.66 624.34 6
4 479.18 240.09    461.17 231.09 Y 1136.63 568.82 1119.60 560.31   5
5 592.26 296.63    574.25 287.63 I 973.57 487.29 956.54 478.77   4
6 1192.55 596.78 1175.52 588.26 1174.54 587.77 K 860.48 430.75 843.46 422.23   3
7 1305.63 653.32 1288.61 644.81 1287.62 644.31 L 260.20 130.60 243.17 122.09   2
8          K 147.11 74.06 130.09 65.55   1
 
Supplementary Figure 2.2: MS analyses of in vitro SUMOylation enabled the identification 
of sites of polySUMOylation. Tandem mass spectra (CID) of tryptic peptides from SUMO1 
mutant showing cross-linkage at (a) K48, (b) K37, (c) K39 and (d) K23 residues. 
PolySUMOylation was observed from in vitro SUMOylation of E2-ligase and RanGAP1 
with His6-SUMO1 mutant. 
Poly-SUMO-1 K23 
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Supplementary Figure 2.3 : In vitro deSUMOylation assay of E2-ligase and RanGAP1 
using SENP1.   a) Silver stained gel of reaction products from E2-25 (deSUMOylation by 
SENP1 following in vitro SUMOylation by Ubc9. b) Silver stained gel of reaction products 
from GST-RanGAP1 (418-587) deSUMOylation by SENP1 following in vitro 
SUMOylation by Ubc9. c) Silver stained gel showing the comparison deSUMOylation of 
WT and His6-SUMO1 mutant by SENP1. d) Anti-His immunoblot of SUMOylated E2-25 
K with and without SENP1. e) Anti GST immunoblot of SUMOylated GST-PML (485-
495). Approximately 1-2 ug of protein substrate was used in each experiment. In vitro 
SUMOylation conditions as indicated in the experimental section.  Following the in vitro 
SUMOylation, the SAE1/2 enzyme was inhibited with EDTA (20 mM) prior to incubation 
with 1 μM SENP1 (Boston Biochem) at 37˚C for 2h. 
 
 
 
x
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Figure 2.4 : Comparison of His-SUMO1 WT and His-SUMO1 mutant 
to SUMOylate PML and to colocalize within nuclear bodies. Immunofluorescence of 
HEK293 cells co-transfected with YFP-PML and His-SUMO1 WT or mutant revealed 
using anti-His antibody. As2O3 induced aggregation of SUMOylated PML in NBs for both 
His6-SUMO1 WT and mutant compared to untreated cells. 
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Supplementary Figure 2.5: Analysis of Gene Ontology terms associated with biological 
processes from a) SUMO-3 and b) SUMO-1 protein candidates using the software 
PANTHER (see Annex IV, Supplementary Tables 1 and 2 for protein list). 
a) 
b) 
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Supplementary Figure 2.6: NTA purified extracts from control HEK293 and HEK293-
His-SUMO cells.  a) Loading control (Fig. 4a) for the comparison of cytosol (C) and 
nuclear (N) extracts revealed using silver staining. b) Loading control for Fig, 4b using 
silver staining. c) Immunoblot (PML) and coomassie stained gel of NTA purified extracts 
from control HEK293 and HEK293-His-SUMO1 cells. 
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Supplementary Figure 2.7: Tandem mass spectra of synthetic peptides to confirm 
SUMOylation of sites K380 and K400. MS/MS spectra of precursor ions (a) m/z 835.892+ 
and (b) m/z 392.543+ obtained using CID and ETD activation, respectively. 
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Supplementary Figure 2.8 : (a)Design of an immunoprecipitation experiment using 
a centrifugal filter device. Sumoylated peptides are specifically retained in the upper 
chamber. (b)Recovery yields of SUMOylated peptides EFK*EVLK (SUMOylated K14 
from E2-25K) and KVIK*MESEEGKEAR (SUMOylated K490 from E2-25K) spiked at 
different levels in a HEK293 tryptic digest. * indicates site of attachment of GGTQE on 
modified Lys residue. 
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Supplementary Figure 2.9: Mass spectrometry analyses of SUMOylated proteins from 
Immunoaffinity purified NTA extracts of mock HEK293 and HEK293 His6-SUMO1 in 
As2O3-stimulated and non-stimulated cells. a) Venn diagram showing the overlapping 
distribution of peptides in each cell extract. Proteins identified with at least 2 peptides were 
considered for the comparison. b) Intensity distribution of peptide ions identified in the 
HEK293 His6-SUMO3 in As2O3-stimulated and non-stimulated cells. The change in 
abundance of tryptic peptides from PML (K490), RanGAP1 (K524) and SAFB2 (K294) are 
indicated on the scatter plot. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
xix
 
Annex II: Supplementary Figure 2.10 for Chapter 2 
(A Novel Proteomics Approach to Identify SUMOylated Proteins and 
their Modification Sites in Human Cells) 
 
 
 
 
 
 
Supplementary Figure 2.10: Tandem Mass Spectra of All Identified 
SUMO-3 Peptides Following Database Search and Manual 
Validation. 
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Peptide No.2  
MS/MS Fragmentation of KQLATKAAR Found in 
Sumo3_wo_AS_21Nov2010_4.RAW -IPI00171611- Tax_Id=9606 
Gene_Symbol=HIST2H3A;HIST2H3D; HIST2H3C Histone H3.2  
Match to Query 2256: 1442.797152 from(481.939660,3+)  
 
Monoisotopic mass of neutral peptide Mr(calc): 1442.80 Variable modifications: K6 : 
Sumo 3 (K) Ions Score: 13 Expect: 19 Matches (Bold Red): 12/48 fragment ions using 38 
most intense peaks  
 
 
 
 
xxii
Peptide No.3  
MS/MS Fragmentation of REKGLALLK Found in 
Sumo3_with_AS_21Nov2010_5.RAW -IPI00008456- Tax_Id=9606 Gene_Symbol=HSF4 
Isoform HSF4B of Heat shock factor protein 4  
Match to Query 6025: 1483.839728 from(742.927140,2+)  
 
Monoisotopic mass of neutral peptide Mr(calc): 1483.85 Variable modifications: K3 : 
Sumo 3 (K) Ions Score: 38 Expect: 0.037 Matches (Bold Red): 14/80 fragment ions using 
19 most intense peaks  
 
 
 
 
xxiii
Peptide No.4  
MS/MS Fragmentation of KLESTESR Found in 
Sumo3_with_AS_21Nov2010_2.RAW -IPI00514817- Tax_Id=9606 
Gene_Symbol=LMNA Lamin A/C  
Match to Query 2258: 1405.678032 from(469.566620,3+)   
 
Monoisotopic mass of neutral peptide Mr(calc): 1405.68 Variable modifications: K1 : 
Sumo 3 (K) Ions Score: 19 Expect: 8 Matches (Bold Red): 11/42 fragment ions using 37 
most intense peaks  
 
 
 
 
 
xxiv
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
xxv
Peptide No.6  
MS/MS Fragmentation of HTPLSKLMK Found in 
Sumo3_with_AS_21Nov2010_5.RAW -IPI00455745- Tax_Id=9606 
Gene_Symbol=LOC100133788 similar to SMT3B protein  
Match to Query 6221: 1510.788848 from(756.401700,2+)    
 
Monoisotopic mass of neutral peptide Mr(calc): 1510.79 Variable modifications: K6 : 
Sumo 3 (K) Ions Score: 20 Expect: 2.7 Matches (Bold Red): 18/76 fragment ions using 50 
most intense peaks  
 
 
 
 
 
xxvi
Peptide No.7  
MS/MS Fragmentation of KVIKMESEEGKEAR Found in 
Sumo3_wo_AS_21Nov2010_4.RAW -IPI00022348- Tax_Id=9606 Gene_Symbol=PML 
Isoform PML-1 of Probable transcription factor PML  
Match to Query 4747: 2090.034976 from(523.516020,4+)  
 
Monoisotopic mass of neutral peptide Mr(calc): 2090.04 Variable modifications: K4 : 
Sumo 3 (K) Ions Score: 60 Expect: 0.001 Matches (Bold Red): 34/78 fragment ions using 
71 most intense peaks  
 
 
 
 
xxvii
Peptide No.8  
MS/MS Fragmentation of KVIKMESEEGKEAR Found in 
Sumo3_with_AS_21Nov2010_4.RAW -IPI00303999- Tax_Id=9606 Gene_Symbol=PML 
Isoform PML-2 of Probable transcription factor PML  
Match to Query 5504: 2547.235856 from(637.816240,4+)  
 
Monoisotopic mass of neutral peptide Mr(calc): 2547.23 Variable modifications: K4 : 
Sumo 3 (K) K11 : Sumo 3   
(K) Ions Score: 16 Expect: 34 Matches (Bold Red): 32/78 fragment ions using 92 most 
intense peaks   
 
 
 
xxviii
 
 
 
 
 
xxix
Peptide No.9  
MS/MS Fragmentation of DAAVSKK Found in Sumo3_with_AS_21Nov2010_1.RAW 
-IPI00303999- Tax_Id=9606 Gene_Symbol=PML Isoform PML-2 of Probable 
transcription factor PML  
Match to Query 1152: 1174.594872 from(392.538900,3+)  
 
Monoisotopic mass of neutral peptide Mr(calc): 1174.59 Variable modifications: K6 : 
Sumo 3 (K) Ions Score: 12 Expect: 44 Matches (Bold Red): 13/36 fragment ions using 
40 most intense peaks  
 
 
 
 
 
xxx
Peptide No.10  
MS/MS Fragmentation of STANVLEETTVKK Found in 
Sumo3_wo_AS_21Nov2010_2.RAW -IPI00290652- Tax_Id=9606 Gene_Symbol=RSF1 
remodeling and spacing factor 1  
Match to Query 4296: 1875.952512 from(626.324780,3+)   
 
Monoisotopic mass of neutral peptide Mr(calc): 1875.95 Variable modifications: K12 : 
Sumo 3 (K) Ions Score: 12 Expect: 47 Matches (Bold Red): 10/72 fragment ions using 42 
most intense peaks  
 
 
 
 
 
xxxi
Peptide No.11  
MS/MS Fragmentation of TVIKKEEK Found in 
Sumo3_with_AS_21Nov2010_3.RAW -IPI00005648- Tax_Id=9606 
Gene_Symbol=SAFB2 Scaffold attachment factor B2  
Match to Query 5631: 1430.774628 from(716.394590,2+)   
 
Monoisotopic mass of neutral peptide Mr(calc): 1430.77 Variable modifications: K4 : 
Sumo 3 (K) Ions Score: 13 Expect: 21 Matches (Bold Red): 17/76 fragment ions using 44 
most intense peaks  
 
 
 
 
xxxii
Peptide No.12  
MS/MS Fragmentation of EGVKTENDHINLK Found in 
Sumo3_wo_AS_21Nov2010_4.RAW -IPI00299147- Tax_Id=9606 
Gene_Symbol=SUMO3 Small ubiquitin-related modifier 3  
Match to Query 4569: 1952.954616 from(489.245930,4+)   
 
Monoisotopic mass of neutral peptide Mr(calc): 1952.96 Variable modifications: K4 : 
Sumo 3 (K) Ions Score: 32 Expect: 0.39 Matches (Bold Red): 37/72 fragment ions using 
112 most intense peaks   
 
 
 
xxxiii
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
xxxiv
Peptide No.13  
MS/MS Fragmentation of LQEKLSPPYSSPQEFAQDVGR Found in 
Sumo3_with_AS_21Nov2010_5.RAW -IPI00438229- Tax_Id=9606 
Gene_Symbol=TRIM28 Isoform 1 of Transcription intermediary factor 1-beta  
Match to Query 12153: 2832.370932 from(945.130920,3+)   
 
Monoisotopic mass of neutral peptide Mr(calc): 2832.37 Variable modifications: K4 : 
Sumo 3 (K) Ions Score: 75 Expect: 4e-05 Matches (Bold Red): 37/228 fragment ions using 
42 most intense peaks   
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xxxvi
Peptide No.14 
MS/MS Fragmentation of LTEDKADVQSIIGLQR Found in 
Sumo3_wo_AS_21Nov2010_4.RAW -IPI00438229- Tax_Id=9606 
Gene_Symbol=TRIM28 Isoform 1 of  
Transcription intermediary factor 1-beta  
Match to Query 9541: 2242.160648 from(1122.087600,2+) Transcription intermediary 
factor 1-beta  Match to Query 9541: 2242.160648 from(1122.087600,2+)   
 
Monoisotopic mass of neutral peptide Mr(calc): 2242.16 Variable modifications: K5 : 
Sumo 3 (K) Ions Score: 70 Expect: 7.5e-05 Matches (Bold Red): 22/158 fragment ions 
using 33 most intense peaks  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
xxxvii
 
 
 
 
 
  
 
 
 
 
xxxviii
Peptide No.15  
MS/MS Fragmentation of TLTGKTITLEVEPSDTIENVK Found in 
Sumo3_with_AS_21Nov2010_4.RAW -IPI00456429- Tax_Id=9606 
Gene_Symbol=UBA52;UBB;RPS27A; UBC ubiquitin and ribosomal protein L40 
precursor  
Match to Query 12073: 2744.410632 from(915.810820,3+)   
Monoisotopic mass of neutral peptide Mr(calc): 2744.41 Variable modifications: K5 : 
Sumo 3 (K) Ions Score: 28 Expect: 1.2 Matches (Bold Red): 38/226 fragment ions using 83 
most intense peaks  
 
 
 
 
 
 
 
 
 
 
xxxix
 
 
 
 
 
 
 
 
xl
Peptide No.16 
MS/MS Fragmentation of AADGGERPLAASPPGTVKAEEHQR Found in 
Sumo3_with_AS_21Nov2010_6.RAW -IPI00295502- Tax_Id=9606 Gene_Symbol=WIZ 
Isoform 1 of Protein Wiz  
Match to Query 12225: 2900.416002 from(967.812610,3+)   
Monoisotopic mass of neutral peptide Mr(calc): 2900.41 Variable modifications: K18 : 
Sumo 3 (K) Ions Score: 29 Expect: 1.6 Matches (Bold Red): 52/254 fragment ions using 99 
most intense peaks 
 
 
 
 
 
 
 
 
 
 
xli
 
 
# b b++ b* b*++ b0 b0++ Seq. y y++ y* y*++ y0 y0++ 
1 72.04 36.53      A         
2 143.08 72.04      A 2830.38 1415.69 2813.36 1407.18 2812.37 1406.69
3 258.11 129.56    240.10 120.55 D 2759.35 1380.18 2742.32 1371.66 2741.33 1371.17
4 315.13 158.07    297.12 149.06 G 2644.32 1322.66 2627.29 1314.15 2626.31 1313.66
5 372.15 186.58    354.14 177.57 G 2587.30 1294.15 2570.27 1285.64 2569.29 1285.15
6 501.19 251.10    483.18 242.10 E 2530.28 1265.64 2513.25 1257.13 2512.27 1256.64
7 657.30 329.15 640.27 320.64 639.28 320.15 R 2401.23 1201.12 2384.21 1192.61 2383.22 1192.11
8 754.35 377.68 737.32 369.16 736.34 368.67 P 2245.13 1123.07 2228.11 1114.56 2227.12 1114.06
9 867.43 434.22 850.41 425.71 849.42 425.21 L 2148.08 1074.54 2131.05 1066.03 2130.07 1065.54
10 938.47 469.74 921.44 461.22 920.46 460.73 A 2035.00 1018.00 2017.97 1009.49 2016.98 1009.00
11 1009.51 505.26 992.48 496.74 991.50 496.25 A 1963.96 982.48 1946.93 973.97 1945.95 973.48
12 1096.54 548.77 1079.51 540.26 1078.53 539.77 S 1892.92 946.96 1875.89 938.45 1874.91 937.96
13 1193.59 597.30 1176.56 588.79 1175.58 588.29 P 1805.89 903.45 1788.86 894.93 1787.88 894.44
14 1290.64 645.83 1273.62 637.31 1272.63 636.82 P 1708.84 854.92 1691.81 846.41 1690.83 845.92
15 1347.67 674.34 1330.64 665.82 1329.65 665.33 G 1611.78 806.40 1594.76 797.88 1593.77 797.39
16 1448.71 724.86 1431.69 716.35 1430.70 715.85 T 1554.76 777.88 1537.74 769.37 1536.75 768.88
17 1547.78 774.39 1530.75 765.88 1529.77 765.39 V 1453.71 727.36 1436.69 718.85 1435.70 718.36
18 2133.07 1067.04 2116.04 1058.52 2115.06 1058.03 K 1354.65 677.83 1337.62 669.31 1336.64 668.82
19 2204.11 1102.56 2187.08 1094.04 2186.09 1093.55 A 769.36 385.18 752.33 376.67 751.35 376.18
20 2333.15 1167.08 2316.12 1158.56 2315.14 1158.07 E 698.32 349.66 681.30 341.15 680.31 340.66
21 2462.19 1231.60 2445.16 1223.09 2444.18 1222.59 E 569.28 285.14 552.25 276.63 551.27 276.14
22 2599.25 1300.13 2582.22 1291.62 2581.24 1291.12 H 440.24 220.62 423.21 212.11   
23 2727.31 1364.16 2710.28 1355.64 2709.30 1355.15 Q 303.18 152.09 286.15 143.58   
24          R 175.12 88.06 158.09 79.55   
 
 
 
 
 
 
 
 
 
xlii
Peptide No.17  
MS/MS Fragmentation of NQTGGGLGKGGAKFound in 
Sumo3_with_AS_21Nov2010_3.RAW -IPI00453473- Tax_Id=9606 
Gene_Symbol=HIST1H4H;HIST2H4A;HIST4H4;HIST1H4F;HIST1H4D;HIST1H4K;HIS
T1H4C;HIST1H4J;HIST1H4A;HIST1H4I;HIST1H4B;HIST2H4B;HIST1H4E;HIST1H4L 
Histone H4  
Match to Query 1020: 1143.601482 from(382.207770,3+)   
 
Monoisotopic mass of neutral peptide Mr(calc): 1143.60 Ions Score: 53 Expect: 0.001 
Matches (Bold Red): 14/72 fragment ions using 21 most intense peaks   
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xliv
Peptide No.18  
MS/MS Fragmentation of ANEKPTEEVKTENNNHINLK Found in 
Sumo3_wo_AS_21Nov2010_4.RAW -IPI00434968- Small ubiquitin-related modifier 4  
Match to Query 5418: 2778.362616 from(695.597930,4+)   
 
Monoisotopic mass of neutral peptide Mr(calc): 2778.35 Variable modifications: K10 : 
Sumo 3 (K) Ions Score: 22 Expect: 7.5 Matches (Bold Red): 14/114 fragment ions using 37 
most intense peaks  
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Annex III: Supplementary Figure 2.11 for Chapter 2 
(A Novel Proteomics Approach to Identify SUMOylated Proteins and 
their Modification Sites in Human Cells) 
 
 
 
 
 
 
 
 
 
 
Supplementary Figure 2.11: Tandem Mass Spectra of All 
Identified SUMO-1 Peptides Following Database Search and 
Manual Validation 
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Peptide No.1 
MS/MS Fragmentation of KVIKMESEEGKEAR 
Found in IPI:IPI00022348, Tax_Id=9606 Gene_Symbol=PML Isoform PML-1 of 
Probable transcription factor PML 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Monoisotopic mass of neutral peptide Mr(calc): 2105.04 
Variable modifications:  
K4     : SUMO EQTGG (K) (K) 
Ions Score: 30  Expect: 0.81   
Matches (Bold Red): 47/142 fragment ions using 105 most intense peaks 
 
# b b++ b* b*++ b0 b0++ Seq. y y++ y* y*++ y0 y0++ 
1 129.1 65.05 112.08 56.54     K             
2 228.17 114.59 211.14 106.08     V 1977.95 989.48 1960.93 980.97 1959.94 980.48 
3 341.25 171.13 324.23 162.62     I 1878.89 939.95 1861.86 931.43 1860.88 930.94 
4 941.54 471.27 924.51 462.76     K 1765.8 883.4 1748.78 874.89 1747.79 874.4 
5 1072.58 536.79 1055.56 528.28     M 1165.52 583.26 1148.49 574.75 1147.5 574.26 
6 1201.62 601.32 1184.6 592.8 1183.61 592.31 E 1034.47 517.74 1017.45 509.23 1016.46 508.74 
7 1288.66 644.83 1271.63 636.32 1270.65 635.83 S 905.43 453.22 888.41 444.71 887.42 444.21 
8 1417.7 709.35 1400.67 700.84 1399.69 700.35 E 818.4 409.7 801.37 401.19 800.39 400.7 
9 1546.74 773.87 1529.72 765.36 1528.73 764.87 E 689.36 345.18 672.33 336.67 671.35 336.18 
10 1603.76 802.39 1586.74 793.87 1585.75 793.38 G 560.32 280.66 543.29 272.15 542.3 271.66 
11 1731.86 866.43 1714.83 857.92 1713.85 857.43 K 503.29 252.15 486.27 243.64 485.28 243.15 
12 1860.9 930.95 1843.87 922.44 1842.89 921.95 E 375.2 188.1 358.17 179.59 357.19 179.1 
13 1931.94 966.47 1914.91 957.96 1913.93 957.47 A 246.16 123.58 229.13 115.07     
14             R 175.12 88.06 158.09 79.55     
 
 
 
xlviii
 
Peptide No. 2 
MS/MS Fragmentation of ADSLLAVVKREPAEQPGDGER 
Found in IPI:IPI00005648, Tax_Id=9606 Gene_Symbol=SAFB2 Scaffold attachment 
factor B2 
 
 
 
Monoisotopic mass ofneutral peptide Mr(calc): 2708.34 
Variable modifications:  
K9     : SUMO EQTGG (K) (K) 
Ions Score: 30  Expect: 1   
Matches (Bold Red): 44/220 fragment ions using 75 most intense peaks 
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# b++ b* b*++ b0 b0++ Seq. y y++ y*++ y0 y0++ 
1 72.04 36.53         A           
2 187.07 94.04     169.06 85.03 D 2638.31 1319.66 1311.14 2620.3 1310.65 
3 274.1 137.56     256.09 128.55 S 2523.28 1262.14 1253.63 2505.27 1253.14 
4 387.19 194.1     369.18 185.09 L 2436.25 1218.63 1210.11 2418.24 1209.62 
5 500.27 250.64     482.26 241.63 L 2323.16 1162.09 1153.57 2305.15 1153.08 
6 571.31 286.16     553.3 277.15 A 2210.08 1105.54 1097.03 2192.07 1096.54 
7 670.38 335.69     652.37 326.69 V 2139.04 1070.02 1061.51 2121.03 1061.02 
8 769.45 385.23     751.43 376.22 V 2039.97 1020.49 1011.98 2021.96 1011.49 
9 1369.73 685.37 1352.71 676.86 1351.72 676.36 K 1940.91 970.96 962.44 1922.9 961.95 
10 1525.83 763.42 1508.81 754.91 1507.82 754.41 R 1340.62 670.81 662.3 1322.61 661.81 
11 1654.88 827.94 1637.85 819.43 1636.87 818.94 E 1184.52 592.76 584.25 1166.51 583.76 
12 1751.93 876.47 1734.9 867.95 1733.92 867.46 P 1055.48 528.24 519.73 1037.46 519.24 
13 1822.97 911.99 1805.94 903.47 1804.96 902.98 A 958.42 479.71 471.2 940.41 470.71 
14 1952.01 976.51 1934.98 967.99 1934 967.5 E 887.39 444.2 435.68 869.37 435.19 
15 2080.07 1040.54 2063.04 1032.02 2062.06 1031.53 Q 758.34 379.68 371.16 740.33 370.67 
16 2177.12 1089.06 2160.09 1080.55 2159.11 1080.06 P 630.28 315.65 307.13 612.27 306.64 
17 2234.14 1117.57 2217.11 1109.06 2216.13 1108.57 G 533.23 267.12 258.61 515.22 258.11 
18 2349.17 1175.09 2332.14 1166.57 2331.16 1166.08 D 476.21 238.61 230.1 458.2 229.6 
19 2406.19 1203.6 2389.16 1195.09 2388.18 1194.59 G 361.18 181.1 172.58 343.17 172.09 
20 2535.23 1268.12 2518.21 1259.61 2517.22 1259.11 E 304.16 152.58 144.07 286.15 143.58 
21             R 175.12 88.06 79.55     
 
 
 
l
Peptide No. 3 
MS/MS Fragmentation of LLVHMGLLKSEDKVK 
Found in IPI:IPI00294879, Tax_Id=9606 Gene_Symbol=RANGAP1 Ran GTPase-
activating protein 1 
 
Monoisotopic mass of neutral peptide Mr(calc): 2197.18 
Variable modifications: M5     : Oxidation (M), with neutral losses 0.00(shown in 
table), 64.00 K9     : SUMO EQTGG (K) (K) Ions Score: 17  Expect: 7.6  Matches (Bold 
Red): 26/194 fragment ions using 45 most intense peaks 
 
# b b++ b* b*++ b0++ Seq. y y++ y* y*++ y0 
1 114.09 57.55       L           
2 227.18 114.09       L 2085.1 1043.05 2068.07 1034.54 2067.09 
3 326.24 163.63       V 1972.02 986.51 1954.99 978 1954.01 
4 463.3 232.16       H 1872.95 936.98 1855.92 928.46 1854.94 
5 610.34 305.67       M 1735.89 868.45 1718.86 859.94 1717.88 
6 667.36 334.18       G 1588.85 794.93 1571.83 786.42 1570.84 
7 780.44 390.73       L 1531.83 766.42 1514.81 757.91 1513.82 
8 893.53 447.27       L 1418.75 709.88 1401.72 701.36 1400.74 
9 1493.81 747.41 1476.79 738.9   K 1305.66 653.34 1288.64 644.82 1287.65 
10 1580.85 790.93 1563.82 782.41 781.92 S 705.38 353.19 688.35 344.68 687.37 
11 1709.89 855.45 1692.86 846.93 846.44 E 618.35 309.68 601.32 301.16 600.34 
12 1824.92 912.96 1807.89 904.45 903.96 D 489.3 245.16 472.28 236.64 471.29 
13 1953.01 977.01 1935.98 968.5 968 K 374.28 187.64 357.25 179.13   
14 2052.08 1026.54 2035.05 1018.03 1017.54 V 246.18 123.59 229.15 115.08   
15           K 147.11 74.06 130.09 65.55   
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Annex IV: Supplementary Tables I-III for Chapter 2 
(A Novel Proteomics Approach to Identify SUMOylated Proteins and 
their Modification Sites in Human Cells) 
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 Supplementary Table I: Peptide and protein identification from NTA affinity-purified 
mock HEK293 and HEK293 His6-SUMO3 mutant nuclear extracts with and without 
As2O3. Table on CD ROM 
 
Supplementary Table II: Peptide and protein identification from dual affinity purification 
(NTA and immunoprecipitation) of mock HEK293 and HEK293 His6-SUMO1 mutant 
nuclear extracts with and without As2O3. Table on CD ROM 
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Supplementary Table III : Identification of SUMOylated peptides with Mascot, ChopNSpice and SUMmOn from NTA affinity-purified 
HEK293 His6-SUMO3 mutant nuclear extracts with and without As2O3. 
Protein  Peptide Sequence K MASCOT* ChopNSpice SUMmOn 
      CID ETD CID ETD CID 
Histone H3.2 KQLATKAAR K6    17.7  
  HSF4B  REKGLALLK K3 37.8     
Lamin A/C KLESTESR K1  18.7  48.8  
 PML  KVIKMESEEGKEAR K4 46.31 39 59.7 60.23  
 PML  KVIKMESEEGKEAR K4|K11  15.5    
 PML  DAAVSKK K6  12.2    
 PML  TDGFDEFKVR K8 25.7     
 RSF1  STANVLEETTVKK K12      
 SAFB2 TVIKKEEK K4 12.9  45.38   
 SUMO3  EGVKTENDHINLK K4 19  29.5   
 TRIM28  LQEKLSPPYSSPQEFAQDVGR K4 74.9  81.14   
 TRIM29 LTEDKADVQSIIGLQR K5 48.3  68   
 WIZ 1  AADGGERPLAASPPGTVKAEEHQR K18 28.8 20.9 32.43   
Ubiquitin TLTGKTITLEVEPSDTIENVK K5 28.2  32.9   
 SUMO2/3  HTPLSKLMK K6 20.2     
SUMO4 ANEKPTEEVKTENNNHINLK K10  22    
 SCIN  GKDANPQERK K2   51   
 protein LOC205717 KIGINR K1   43   
Histone H4 GLGKGGAK K4    52.6  
 PML  TDGFDEFKVR K8     0.987 
CHD-7 EDVEKNLAPK K5     0.989 
 
